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A B S T R A C T
Background
Foot ulcers in people with diabetes mellitus are a common and serious global health issue. Dressings form a key part of ulcer treatment,
with clinicians and patients having many different types to choose from. A clear and current overview of current evidence is required
to facilitate decision-making regarding dressing use.
Objectives
To summarize data from systematic reviews of randomised controlled trial evidence on the effectiveness of dressings for healing foot
ulcers in people with diabetes mellitus (DM).
Methods
We searched the following databases for relevant systematic reviews and associated analyses: theCochrane Central Register of Controlled
Trials (CENTRAL; The Cochrane Library 2015, Issue 2); Database of Abstracts of Reviews of Effects (DARE; The Cochrane Library
2015, Issue 1); OvidMEDLINE (In-Process &OtherNon-Indexed Citations, 14 April 2015); Ovid EMBASE (1980 to 14 April 2015).
We also handsearched the Cochrane Wounds Group list of reviews. Two review authors independently performed study selection, risk
of bias assessment and data extraction. Complete wound healing was the primary outcome assessed; secondary outcomes included
health-related quality of life, adverse events, resource use and dressing performance.
Main results
We found 13 eligible systematic reviews relevant to this overview that contained a total of 17 relevant RCTs. One review reported the
results of a network meta-analysis and so presented information on indirect, as well as direct, treatment effects. Collectively the reviews
reported findings for 11 different comparisons supported by direct data and 26 comparisons supported by indirect data only. Only
four comparisons informed by direct data found evidence of a difference in wound healing between dressing types, but the evidence
was assessed as being of low or very low quality (in one case data could not be located and checked). There was also no robust evidence
of a difference between dressing types for any secondary outcomes assessed.
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Authors’ conclusions
There is currently no robust evidence for differences between wound dressings for any outcome in foot ulcers in people with diabetes
(treated in any setting). Practitioners maywant to consider the unit cost of dressings, theirmanagement properties and patient preference
when choosing dressings.
P L A I N L A N G U A G E S U M M A R Y
Dressings to treat foot ulcers in people with diabetes
Background
Diabetes mellitus (generally known as ’diabetes’), when untreated, causes a rise in the sugar (glucose) levels in the blood. It is a serious
health issue that affects millions of people around the world (e.g., almost two million people in the UK and 24 million people in the
USA). Foot ulcers are a common problem for people with diabetes; at least 15% of people with diabetes have foot ulcers at some time
during their lives. Wound dressings are used extensively in the care of these ulcers. There are many different types of dressings available,
from basic wound contact dressings to more advanced gels, films, and specialist dressings that may be saturated with ingredients that
exhibit particular properties (e.g. antimicrobial activity). Given this wide choice, a clear and up-to-date overview of the available research
evidence is needed to help clinicians/practitioners to decide which type of dressing to use.
Review question
What is the evidence that the type of wound dressing used for foot ulcers in people with diabetes affects healing?
What we found
This overview drew together and summarised evidence from 13 systematic reviews that contained 17 relevant randomised controlled
trials (the best type of study for this type of question) published up to 2013. Collectively, these trials compared 10 different types
of wound dressings against each other, making a total of 37 separate comparisons. The different ways in which dressing types were
compared made it difficult to combine and analyse the results. Only four of the comparisons informed by direct data found evidence
of a difference in ulcer healing between dressings, but these results were classed as low quality evidence.
There was no clear evidence that any of the ’advanced’ wound dressings types were any better than basic wound contact dressings for
healing foot ulcers. The overview findings were restricted by the small amount of information available (a limited number of trials
involving small numbers of participants).
Until there is a clear answer about which type of dressing performs best for healing foot ulcers in people with diabetes, other factors,
such as clinical management of the wound, cost, and patient preference and comfort, should influence the choice of dressing.
This plain language summary is up-to-date as of April 2015.
B A C K G R O U N D
Also see Glossary (Appendix 1).
Description of the condition
Diabetes mellitus (DM; high glucose levels in the blood) is a com-
mon condition that affects 1.8 million people in the UK (approx-
imately 3% of the population) and 24 million in the USA. In-
cidence of DM is projected to increase rapidly over the next 25
years (WHO 2005). Global projections suggest that the world-
wide prevalence of DM could rise to 4.4% by 2030, which would
mean that approximately 366 million people would be affected
(Wild 2004).
Success in treating DM has improved the life expectancy of pa-
tients. However, the increased prevalence of DM, coupled with
the extended time people now live with the disease, has led to in-
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creased numbers of DM-related complications, such as neuropa-
thy (nerve damage) and peripheral arterial disease (PAD).
Both PAD and neuropathy are risk factors for the development of
chronic foot ulceration in people withDM(Pecoraro 1990; Reiber
1999), as are other physical issues such as joint deformity (Abbott
2002). PAD and neuropathy can occur separately (ischaemic foot
and neuropathic foot, respectively), or in combination (in the
neuroischaemic foot). Foot ulceration is reported to affect 15%
or more of the diabetic population at some time in their lives
(Reiber 1996; Singh 2005). Estimates from UK surveys indicate
that around 1% to 4% of people with DM have foot ulcers at any
given time (Abbott 2002; Kumar 1994). In 2008, the prevalence
of having at least one foot ulcer was 8% amongst people with DM
receiving Medicare in the USA (Margolis 2011).
An ulcer forms as a result of damage to the epidermis (skin) and
subsequent loss of underlying tissue. Specifically, the International
Consensus on the Diabetic Foot defines a foot ulcer as a wound
that extends through the full thickness of the skin below the level
of the ankle (Apelqvist 2000a). This is irrespective of duration (al-
though some definitions of chronic ulceration require a duration
of six weeks or more), and the ulcer can extend to muscle, ten-
don and bone. Foot ulcers in people with DM can be graded for
severity using a number of systems. The Wagner wound classifi-
cation system was one of the first described, and has, historically,
been widely used, although it is now rarely used in clinical practice
(Wagner 1981). The system assesses ulcer depth and the presence
of osteomyelitis (bone infection) or ischemia and infection and
grades them as: grade 0 (pre- or post-ulcerative lesion); grade 1
(partial/full-thickness ulcer); grade 2 (probing to tendon or cap-
sule); grade 3 (deep with osteitis (bone inflammation)); grade 4
(partial foot gangrene); and grade 5 (whole foot gangrene). Newer
grading systems, such as the PEDIS system (Schaper 2004), the
University of Texas Wound Classification System and SINBAD
(Ince 2008; Oyibo 2001), have been developed, with variable val-
idation (Karthikesalingam 2010).
Foot ulcers in people with DM have a serious impact on their
health-related quality of life (Nabuurs-Franssen 2005;Ribu 2006),
and treating people with DM and foot ulcers incurs costs to the
health system - not only for dressings applied, but also for staff
(for podiatry, nurses, doctors), tests and investigations, antibiotics
and specialist footwear. Twelve years ago the cost of diabetic foot
ulceration to the UK National Health Service was believed to be
about GBP 12.9 million annually (Lewis 2013); this figure will
have increased significantly since. The economic impact is also
high in terms of the personal costs to patients and carers, and in-
cludes costs associated with lost work time and productivity while
the patient is non-weight bearing (taking weight off the affected
foot), or hospitalised. Asmany as 85% of foot-related amputations
are preceded by ulceration (Apelqvist 2000b; Pecoraro 1990).
In terms of ulcer healing, a meta-analysis of trials in which people
with neuropathic foot ulcers received good wound care reported
that 24% of ulcers attained complete healing by 12 weeks and
31% by 20 weeks (Margolis 1999). Reasons for delayed healing
might include: infection (especially osteomyelitis), co-morbidities
and the size and depth of ulcer at presentation. Even when ulcers
do heal, the risk of ulcer recurrence is high. Pound 2005 reported
that 62% of ulcer patients (n = 231) became ulcer-free at some
stage over a 31-month observation period. However, 40% of the
ulcer-free group went on to develop a new or recurrent ulcer after
a median period of 126 days. The ulcer recurrence rate over five
years can be as high as 70% (Dorresteijn 2010; Van Gils 1999).
Failure of ulcers to heal may result in amputation, and people with
DM have a 10- to 20-fold higher risk of losing a lower limb, or
part of a lower limb, due to non-traumatic amputation than those
without DM (Morris 1998; Wrobel 2001).
Description of the interventions
The treatment of foot ulcers in people with DM comprises sev-
eral strategies, some of which may be used concurrently. These
include: pressure relief (i.e. off-loading - taking weight off the af-
fected foot); wearing special footwear, or shoe inserts, that are de-
signed to redistribute load on the surface of the foot; removal of
dead cellularmaterial from the surface of the wound (debridement
or desloughing); infection control; and the use of wound dress-
ings. Other general treatment strategies include: patient education
(e.g. in relation to foot care, or other aspects of self-management);
optimisation of blood glucose control; correction (where possible)
of arterial insufficiency, for example with arterial reconstruction
surgery; and other surgical interventions such as debridement,
drainage of pus and amputation.
Dressings are widely used in wound care, both to protect the
wound and to promote healing. Classification of a dressing nor-
mally depends on the key material used. Several attributes of an
ideal wound dressing have been described (BNF 2014), including:
1. the ability of the dressing to absorb and contain exudate
without leakage or strike-through;
2. lack of particulate contaminants left in the wound by the
dressing;
3. thermal insulation;
4. impermeability to water and bacteria;
5. avoidance of wound trauma on dressing removal;
6. frequency with which the dressing needs to be changed (less
frequent dressing changes seen as positive);
7. provision of pain relief; and
8. comfort.
There is a vast choice of dressings available to treat chronic wounds
like foot ulcers in people with DM. For ease of comparison this
review has categorised dressings according to the British National
Formulary 2010 (BNF 2014), which is freely available via the In-
ternet. We will use ’generic’ names where possible, also provid-
ing UK trade names and manufacturers, where these are available,
to allow cross-reference with the BNF. However, it is important
to note that the way dressings are categorised, as well as dress-
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ing names, manufacturers and distributors of dressings may vary
from country to country, so these are provided as a guide only. A
description of all categories of dressings is given below and brief
summaries of key terms, including dressing types can be found in
the glossary (Appendix 1).
1. Basic wound contact dressings
Low-adherence dressings and wound contact materials
Low-adherence dressings and wound contact materials usually
consist of cotton pads that are placed directly in contact with the
wound. These can be non-medicated (e.g. paraffin gauze dress-
ing), or medicated (e.g. containing povidone iodine or chlorhexi-
dine). Examples include paraffin gauze dressing, BP 1993 and Xe-
roform® (Covidien) dressing (a non-adherent petrolatum blend
with 3% bismuth tribromophenate on fine mesh gauze).
Absorbent dressings
Absorbent dressings are applied directly to the wound, and may
be used as secondary absorbent layers in the management of heav-
ily exuding wounds. Examples include Primapore® (Smith &
Nephew),Mepore® (Mölnlycke) and absorbent cotton gauze (BP
1988).
2. Advanced wound dressings
Alginate dressings
Alginate dressings are highly absorbent and come in the form of
calcium alginate or calcium sodium alginate, which can be com-
bined with collagen. Alginates form a gel when in contact with the
wound surface; this can be lifted off when the dressing is removed,
or rinsed away with sterile saline. Bonding the alginate to a sec-
ondary viscose pad increases absorbency. Examples include: Cura-
sorb (Covidien), SeaSorb (Coloplast) and Sorbsan (Unomedical).
Hydrogel dressings
Hydrogel dressings consist of cross-linked insoluable polymers (i.e.
starch or carboxymethylcellulose) and up to 96% water. These
dressings are designed to absorb wound exudate, or rehydrate a
wound, depending on the wound moisture levels. They are sup-
plied in flat sheets, as an amorphous hydrogel, or as beads. Exam-
ples include: ActiformCool® (Activa) and Aquaflo® (Covidien).
Films (permeable film and membrane dressings)
Films (permeable film and membrane dressings) are permeable
to water vapour and oxygen, but not to water or micro-organ-
isms. Examples include Tegaderm® (3M) and Opsite® (Smith &
Nephew).
Soft polymer dressings
Soft polymer dressings are composed of a soft silicone polymer held
in a non-adherent layer, and are moderately absorbent. Examples
include: Mepitel® (Mölnlycke) and Urgotul® (Urgo).
Hydrocolloid dressings
Hydrocolloid dressings are occlusive andusually composed of a hy-
drocolloid matrix bonded onto a vapour-permeable film or foam
backing. When in contact with the wound surface this matrix
forms a gel to provide a moist environment for the wound. Ex-
amples include: Granuflex® (ConvaTec) and NUDERM® (Sys-
tagenix). Fibrous alternatives have been developed that resemble
alginates and are not occlusive, but which are more absorbant than
standard hydrocolloid dressings, for example, Aquacel® (Conva-
Tec).
Foam dressings
Foamdressings contain hydrophilic polyurethane foam and are de-
signed to absorb wound exudate and maintain a moist wound sur-
face. These are available in a variety of versions: some include ad-
ditional absorbent materials, such as viscose and acrylate fibres or
particles of superabsorbent polyacrylate, while others are silicone-
coated for non-traumatic removal. Examples include: Allevyn®
(Smith &Nephew), Biatain® (Coloplast) and Tegaderm® (3M).
Capillary-action dressings
Capillary-action dressings consist of an absorbent core of hy-
drophilic fibres held between two low-adherent contact layers. Ex-
amples include: Advadraw® (Advancis) and Vacutx® (Protex).
Odour-absorbent dressings
Odour-absorbent dressings contain charcoal and are used to absorb
wound odour. Often these types of wound dressings are used in
conjunction with a secondary dressing to improve absorbency. An
example of an odour-absorbent dressing is CarboFLEX® (Con-
vaTec).
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3. Anti-microbial dressings
Honey-impregnated dressings
Honey-impregnated dressings contain medical-grade honey,
which is proposed to have antimicrobial and anti-inflammatory
properties and can be used for acute or chronic wounds. Examples
include: Medihoney® (Medihoney) and Activon Tulle® (Advan-
cis).
Iodine-impregnated dressings
Iodine-impregnated dressings release free iodine when exposed to
wound exudate. The free iodine is thought to act as a wound
antiseptic. Examples include Iodoflex® (Smith & Nephew) and
Iodozyme® (Insense).
Silver-impregnated dressings
Silver-impregnated dressings are used to treat infected wounds,
as silver ions are thought to have antimicrobial properties. Sil-
ver versions of most dressing types are available (e.g. silver foam,
silver hydrocolloid, etc). Examples include: Acticoat® (Smith &
Nephew) and Urgosorb Silver® (Urgo).
Other antimicrobial dressings
Other antimicrobial dressings are composed of a dressing impreg-
nated with an ointment thought to have antimicrobial proper-
ties. Examples include: chlorhexidine gauze dressing (Smith &
Nephew), Cutimed Sorbact® (BSNMedical), and a dressing im-
pregnated with the anti-microbial polyhexamethylene biguanide
(PHMB).
4. Specialist dressings
Protease-modulating matrix dressings
Protease-modulating matrix dressings alter the activity of prote-
olytic (protein-digesting) enzymes in chronic wounds. Examples
include: Promogran® (Systagenix) and Sorbion® (H & R).
It is difficult to make an evidence-informed decision of the best
treatment regimen for patients, given the diversity of dressings
available to clinicians (including variation within each type listed
above). In a UK survey performed to determine treatments used
for debriding diabetic foot ulcers, a wide range of treatments was
reported (Smith 2003), and it is possible that a similar scenario is
true for choice of dressing. A survey of Diabetes Specialist Nurses
found that low/non-adherent dressings, hydrocolloids and algi-
nate dressings were the most popular for all wound types, despite
a paucity of evidence for any of these dressing types (Fiskin 1996).
However, several new, heavily-promoted types of dressing have
become available in recent years. Some dressings now have ’ac-
tive’ ingredients, such as silver, that are promoted as options to re-
duce infection, and thus possibly promote healing. As increasingly
sophisticated technology is applied to wound care, practitioners
need to know how effective these - often expensive - dressings are
compared with more traditional dressings.
How the intervention might work
Animal experiments conducted over 40 years ago suggested that
acute wounds heal more quickly when their surface is kept moist,
rather than left to dry and scab (Winter 1963). A moist envi-
ronment is thought to provide optimal conditions for the cells
involved in the healing process, as well as allowing autolytic de-
bridement (disposal of dead cells by the body), which is thought
to be an important part of the healing pathway (Cardinal 2009).
The desire to maintain a moist wound environment is a key driver
for the use of wound dressings. Different wound dressings vary in
their levels of absorbency, so a very wet wound can be treated with
an absorbent dressing (such as an alginate dressing) that draws ex-
cess moisture away from the wound in order to avoid skin damage,
whilst a drier wound can be treated with a more occlusive dressing
to maintain a moist environment.
Why it is important to do this overview
Foot ulcers in people with DM are a prevalent and serious global
issue. Treatment with dressings forms a key part of the treatment
pathway when caring for such ulcers: there aremany types of dress-
ings that can be used, and these vary considerably in cost. Given
the number of dressing types available, we considered the poten-
tial volume of data available to be too great for a single Cochrane
review of dressings for foot ulcers in people with DM, although
such reviews have previously been published. An early UK Health
Technology Assessment review of different strategies to prevent
and treat diabetic foot ulcers included 39 clinical trials of which
six randomised controlled trials (RCTs) evaluated dressings for the
treatment of foot ulceration in people with DM (O’Meara 2000).
The review did not find any evidence to suggest that one dress-
ing type was more, or less, effective in terms of treating diabetic
foot ulcers. The methodological quality of trials was poor and all
were small. Only one comparison was repeated in more than one
trial. Another systematic review, also out of date (Mason 1999),
reported similar findings. More recently a systematic review was
published on the effectiveness of interventions to enhance the
healing of chronic ulcers of the foot (search date December 2006;
Hinchliffe 2008a). This included only eight trials that looked at
dressings (as well as further non-randomised studies), and, again,
did not identify any evidence that one dressing type was superior
to another in terms of promoting ulcer healing. It is important
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to note that the review was very broad in its outlook, looking at
other non-dressing interventions, and that since its publication
more than six years’ worth of new literature has become available.
There are several Cochrane reviews that examine the effects of
different dressing types on the healing of foot ulcers in people
with DM, either as a single condition (Dumville 2013a; Dumville
2013b; Dumville 2013c; Dumville 2013d; Edwards 2010), or as
part of a wider review of the effectiveness of a dressing (Storm-
Versloot 2010). However, there is a need to draw together all
existing review evidence regarding the effectiveness of dressings
for the treatment of this condition and to present these data to
decision makers.
Current guidelines for the treatment of foot ulcers in people with
DM maintain that clinical judgement should be used to select a
moist wound dressing (e.g. Steed 2006). More recent National
Institute of Clinical and Health Excellence (NICE) guidelines for
inpatient management of diabetic foot problems concluded that,
given there was no evidence that one dressing type was better
than another in terms of healing these wounds, dressing choice
“should take into account specialist expertise, clinical experience,
clinical assessment of the wound, clinical circumstances, site of the
ulcer, and patient preference, and should use the approach with
the lowest acquisition cost” (NICE 2013).
O B J E C T I V E S
To summarize data from systematic reviews that contain ran-
domised controlled trial evidence on the effectiveness of dressings
to heal foot ulcers in people with diabetes mellitus (DM).
M E T H O D S
The conduct of this overview has been guided by the recommen-
dations of The Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011), including the recommendations for
conducting overviews of reviews (Becker 2011).
Criteria for considering reviews for inclusion
Types of studies
We included:
1. Cochrane systematic reviews of RCTs of any dressing type
(as defined in types of interventions section) in the treatment of
foot ulcers in people with DM.*
2. Non-Cochrane systematic reviews of RCTs of any dressing
type in the treatment of foot ulcers in people with DM.
However, to be included a non-Cochrane systematic review had
to be deemed to have employed a systematic approach including
a comprehensive and detailed search strategy, have included only
RCTs, have clear and relevant study selection criteria, and have
assessed methodological features of the included studies and
reported a synthesis of evidence (narrative only or narrative
combined with statistical pooling).*
3. Mixed treatment comparison meta-analyses. Mixed
treatment comparison meta-analyses were only eligible for
inclusion in this overview when undertaken as part of/as a result
of a systematic review including RCTs.*
*If reviews included other studies as well as RCTs (e.g. controlled clin-
ical trials) they were investigated to see whether RCTs were presented
separately within the analysis (for example as a sensitivity analysis).
If so, these RCT data were included; if not, the review was excluded.
If reviews had a wider participant inclusion criterion than foot ul-
cers (e.g. post-operative foot wounds resulting from amputation), the
presentation of included studies was investigated and a decision made
regarding inclusion of the review. They were only included if data on
foot ulcers were presented separately. Primary RCTs published since
the included reviews but not yet included in them were excluded, in
line with Cochrane guidance.
Types of participants
People of any age with either type 1 or type 2 DM who have a
foot ulcer.
Types of interventions
We included dressing treatments, classified according to the BNF
classification (BNF 2014), into four broad sub-groups (Table 1).
However, this list is not exhaustive, and, given the international
perspective of this overview, we plan to include reviews of dress-
ings that may not fall into the subgroups specified by the BNF.
However, dressings that contain living cells (skin-substitute dress-
ings) were not included in this review as we consider these to be a
separate class of treatment. Additionally, we excluded evaluations
of topical applications. If a review focused on an intervention type
that can be applied as a dressing, or a topical application (i.e. sil-
ver), we only considered sections of the review that fulfilled our
inclusion criteria. We only considered dressings compared with a
different dressing or no dressing, we did not include comparisons
of dressings with adjunct therapies (e.g. hyperbaric oxygen, nega-
tive pressure wound therapy, etc).
Types of outcomes
Primary outcomes
Complete wound healing
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Trialists measure and report wound healing inmany different ways
that include: time to complete wound healing, the proportion of
wounds healed during follow-up, and rates of change of wound
size. For this review we regarded reviews that reported one or more
of the two outcomes listed below as providing the best measures
of outcome in terms of relevance and rigour.
1. Time to wound healing within a specific time period
correctly analysed using survival, time-to-event, approaches -
ideally with adjustment for relevant co-variates such as baseline
size. We assumed that the period of time in which healing could
occur was the duration of the trial, unless otherwise stated.
2. Number of wounds completely healed during follow-up
(frequency of complete healing), with healing being defined by
the study authors.
Secondary outcomes
We extracted and reported only useful summary data, as defined
below, for secondary outcomes.
1. Participant health-related quality of life/health status
(measured using a standardised generic questionnaire such as
EQ-5D, SF-36, SF-12 or SF-6 (Dolan 1995; Ware 2001), or
wound-specific questionnaires such as the Cardiff wound impact
schedule (Price 2004), at noted time points. We did not include
ad hoc measures of quality of life that were likely not to be
validated, and not common to multiple trials.
2. Adverse events where a clear methodology for the collection
of adverse event data had been provided. We summarized adverse
event data only when it was clear that the participant (or wound)
was the denominator. That is, data were presented so that the
number of events per participant are known (or an overview of
this, e.g. number of participants with one or more event).
Conversely, where the potential for multiple count data per
participant could not be assessed, we did not consider data
further. Finally, we noted the method of data collection, and
commented on the potential risk of measurement and
performance bias.
3. Resource use (including measurements of resource use such
as number of dressing changes, nurse visits, length of hospital
stay and re-operation/intervention).
4. Dressing performance such as exudate management or
patient comfort on dressing removal.
Search methods for identification of reviews
For this overview we searched the following electronic databases
to identify both Cochrane and non-Cochrane systematic reviews
and reports of mixed treatment comparisons.
1. The Cochrane Central Register of Controlled Trials
(CENTRAL; The Cochrane Library 2015, Issue 4);
2. Database of Abstracts of Reviews of Effects (DARE; The
Cochrane Library 2015, Issue 1);
3. Ovid MEDLINE (1950 to 14 April 2015);
4. Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, 14 April 2015);
5. Ovid EMBASE (1980 to 14 April 2015);
We used the following search strategy to identify Cochrane and
non-Cochrane systematic reviews in The Cochrane Library (which
includes DARE - a repository of structured, critical summaries of
published systematic reviews):
#1 MeSH descriptor: [Occlusive Dressings] explode all trees
#2 MeSH descriptor: [Bandages, Hydrocolloid] explode all trees
#3 MeSH descriptor: [Biological Dressings] explode all trees
#4 MeSH descriptor: [Alginates] explode all trees
#5 MeSH descriptor: [Hydrogels] explode all trees
#6 MeSH descriptor: [Silver] explode all trees152
#7 MeSH descriptor: [Silver Sulfadiazine] explode all trees
#8 MeSH descriptor: [Honey] explode all trees
#9 (dressing* or hydrocolloid* or alginate* or hydrogel* or “foam”
or “bead” or “film” or “films” or tulle or gauze or non-adherent or
“non adherent” or silver or honey or matrix):ti,ab,kw
#10 {or #1-#9}
#11 MeSH descriptor: [Foot Ulcer] explode all trees
#12 MeSH descriptor: [Diabetic Foot] explode all trees
#13 (diabet* near/3 ulcer*):ti,ab,kw
#14 (diabet* near/3 (foot or feet)):ti,ab,kw
#15 (diabet* near/3 wound*):ti,ab,kw
#16 (diabet* near/3 amputat*):ti,ab,kw
#17 {or #11-#16}
#18 #10 and #17
We also used the search strategy designedby theCentre forReviews
and Dissemination, York, UK to identify the systematic reviews
summarised in DARE. This strategy is shown in Appendix 2 and
was used to identify non-Cochrane systematic reviews in Ovid
MEDLINE, particularly those systematic reviews not yet indexed
on DARE. We have also developed a provisional search strategy
intended to identify reports of mixed treatment comparison meta-
analysis inOvidMEDLINE (Appendix 3). BothOvidMEDLINE
search strategies were also adapted for Ovid EMBASE.
We handsearched the Cochrane Wounds Group list of reviews
via the Cochrane Database of Systematic Reviews to ensure that
all relevant reviews had been identified. During the conduct of
this overview it was possible that the Cochrane Reviews included
might be updated. For this reason we conducted this search several
times during the review process to ensure that the most up-to-
date versions of each review were included. We contacted relevant
review authors for information, where necessary.
We did not restrict searches by language, date of publication or
study setting.
Data collection and analysis
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Selection of reviews
Two overview authors screened review titles and abstracts to iden-
tify potentially relevant inclusions. The same two overview au-
thors screened the full text of all potentially relevant sources for in-
clusion in the overview. Any disagreements were resolved through
discussion with a third overview author.
Data extraction and management
We extracted data into a pre-defined and piloted data extraction
form to ensure consistent data capture from each review.Datawere
extracted by one overview author and independently checked by a
second, with a third acting as arbitrator where required. For each
included review we extracted the following data:
1. study identification, authors’ details;
2. review objectives;
3. search strategies, including search dates;
4. study inclusion and exclusion criteria;
5. included settings;
6. included populations;
7. all relevant comparisons;
8. the number of relevant included RCTs;
9. outcomes reported and details of reported outcome values;
10. method and results of risk of bias/quality assessment.
Where a comparison was included in more than one review, its
details were recorded multiple times; as it was relevant to each
review in which it is contained. If any information from a review
was unclear or missing, we accessed the published reports of the
individual trials. We did not contact trial authors for details of
missing data, but rather assumed that reviewers had done all they
could to retrieve the data. We entered data into Review Manager
5.3 software (RevMan 2014).
Assessment of methodological quality of included
reviews
As discussed in the Cochrane Handbook, two overview authors
independently assessed the methodological quality of included re-
views using the ’assessment of multiple systematic reviews’ (AM-
STAR) instrument (Shea 2007), which is composed of the follow-
ing 11 criteria:
1. Was an a priori design provided?
2. Was there duplicate study selection and data extraction?
3. Was a comprehensive literature search performed?
4. Was the status of publication (i.e. grey literature) used as an
inclusion criterion?
5. Was a list of studies (included and excluded) provided?
6. Were the characteristics of the included studies provided?
7. Was the scientific quality of the included studies assessed
and documented?
8. Was the scientific quality of the included studies used
appropriately in formulating conclusions?
9. Were the methods used to combine the findings of studies
appropriate?
10. Was the likelihood of publication bias assessed?
11. Was the conflict of interest stated?
The response to each criterion can be ’yes’ (clearly done), in which
case the criterion will be given a score of 1; ’no’ (clearly not done);
’can’t answer’, or ’not applicable’, based on the published review
report. We rated a review with an AMSTAR score of 8 to 11 as one
of high quality; a score of 4 to 7 as medium quality, and a score
of 3 or less as low quality (Shea 2007). Disagreements between
overview authors were discussed and resolved through consensus.
Quality of evidence in included reviews
We also report a summary of the Cochrane risk of bias assessment
carried out for each trial in the most recent included review; this
is given in the tables for each assessed comparison.
We had planned that two overview authors would use theGRADE
approach to assess the quality of themost complete direct evidence
for any pooled complete healing data (Atkins 2004). However,
we did not undertake this process - instead we used the GRADE
assessment reported in one of the included reviews (Dumville
2012). The included review was conducted by one of the overview
authors and checked independently by another author on that
review. The GRADE approach specifies four levels of quality for
RCTs:
1. high quality for randomised trials;
2. moderate quality for downgraded randomised trials;
3. low quality for double-downgraded randomised trials;
4. very low quality for triple-downgraded randomised trials.
We also reported the results of an ad hoc quality assessment un-
dertaken by study authors for quality assessment of network meta-
analysis estimates (Dumville 2012). This involved adapting the
GRADE approach to allow the appraisal of mixed treatment com-
parison (MTC) estimates. Specific adaptations involved assess-
ment of unexplained heterogeneity and inconsistency between di-
rect and indirect evidence as one category of information. The
modified approach also assessed the impact of sensitivity analysis
on the estimate of effect. Relevant limitations in design and pub-
lication bias were applied to the estimates that particular direct
links had contributed to.
Data synthesis
There are a number of different dressings for the treatment of foot
ulcers in people with DM. To maximise value to the reader at this
stage we presented a summary of current evidence for all available
comparisons, taking account of any instances of overlap of evi-
dence between reviews. Firstly each unique direct comparison for
which relative treatment effect data are available is reported (e.g.
gauze versus foam; foam versus alginate, etc) with any relevant in-
direct comparison data also summarised - by outcome, where re-
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quired. Subsequently, where availability of mixed treatment com-
parison meta-analysis data resulted in comparisons informed only
by indirect data, we have summarised these briefly. We considered
the totality of evidence for each comparison, and reported sum-
mary of effect estimates as a narrative review. Thus, within each
comparison, review data are presented in the following order:
1. direct pairwise analyses by source;
2. direct and indirect estimates;
3. indirect data only.
Where applicable, we aimed to convert relevant summaries to the
risk ratio (RR) or hazard ratio (HR), although we were limited by
the statistical information available in each included review. We
did not plan or undertake re-analysis of data beyond conversions
to RR or HR.
In terms of presenting data, each individual included review, or
mixed treatment comparison meta-analysis, has been summarised
using a Characteristics of included reviews table. We then present
a summary overview of outcome data (by comparison) across re-
views.We anticipated using forest plots and ’Summary of findings’
tables to help present data; however, due to sparseness of data, we
have presented only the latter.
R E S U L T S
Description of included reviews
See Figure 1,for a summary of the review process. A summary of
results in tabular format can be found at the end of the results
section.
Figure 1. Study flow diagram.
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Cochrane systematic reviews
Following screening we identified eight potentially relevant
Cochrane systematic reviews. Six of these were identified as
meeting the inclusion criteria for this review (Dumville 2013a;
Dumville 2013b; Dumville 2013c; Dumville 2013d; Edwards
2010; Storm-Versloot 2010). We excluded the remaining two
reviews as they did not contain any relevant included studies
(Bergin 2006; Jull 2013). Of the six Cochrane reviews we in-
cluded, five were focused specifically on foot ulcers in people with
diabetes (Dumville 2013c; Dumville 2013a; Dumville 2013b;
Dumville 2013d; Edwards 2010), and one focused more broadly
on chronic wounds (Storm-Versloot 2010). Four of the included
Cochrane reviews investigated dressings specifically (Dumville
2013a; Dumville 2013b; Dumville 2013c; Dumville 2013d), and
two investigated a wider group of interventions which included
dressings. (Edwards 2010; Storm-Versloot 2010).
Non-Cochrane systematic reviews
Following screening we identified 19 potentially eligible non-
Cochrane reviews that we obtained as full text. Following fur-
ther screening, we included seven of these reviews (Dumville
2012;Game2012;Hinchliffe 2008b;Mason 1999a;Nelson2006;
O’Meara 2000; Voigt 2012), including one mixed treatment com-
parison meta-analysis (all findings were produced from a fixed-
effect model; Dumville 2012). The remaining 11 reviews were ex-
cluded as they were not considered either to be systematic reviews
or to be eligible for this overview (Ashton 2004; Bradley 1999;
Braun 2014; Brimson 2013; Eddy 2008; Greer 2013; Heyer 2013;
Holmes 2013; Jones 2009; Vandamme 2013; Wang 2005); one
review is awaiting assessment as we are currently trying to obtained
information about the included studies (Tian 2014).
Summary of included studies
We included a total of 13 reviews in this overview (see Table 2
for a summary of included reviews). None of the included re-
views specified particular healthcare settings in their inclusion
criteria, but three reviews explicitly noted that studies from any
healthcare settings were included (Dumville 2012; Nelson 2006;
Storm-Versloot 2010). The methods used for assessing the quality
or risk of bias of individual trials also varied between reviews. All
Cochrane reviews followed the approach to risk of bias assessment
that was in use at the time of the review. The approaches in the
non-Cochrane reviews varied (see Table 2).
The included reviews provided direct evidence for 11 comparisons
of dressings (listed below) to treat foot ulcers in people with dia-
betes. Since we included amixed treatment comparison themajor-
ity of these comparisons were also informed by direct and indirect
data. We present both direct only and mixed direct and indirect
data where possible.
Note: one comparison (comparison 4 marked *) was informed by
direct evidence only: all other comparisons were also informed by a
combination of direct and indirect evidence as they were included in
the mixed treatment comparison analysis (Dumville 2012).
1. Basic wound contact dressing compared with alginate
dressing.
2. Basic wound contact dressing compared with hydrogel.
3. Basic wound contact dressing compared with hydrofibre
dressing.
4. Basic wound contact dressing compared with Hyalofill*.
5. Basic wound contact dressing compared with iodine
dressing.
6. Basic wound contact dressing compared with foam dressing.
7. Basic wound contact dressing compared with a protease-
modulating matrix dressing.
8. Foam dressings compared with alginate dressing.
9. Foam dressing compared with hydrocolloid (matrix).
10. Iodine-impregnated dressing compared with hydrofibre
dressing.
11. Alginate compared with silver-hydrofibre/dressing.
We also summarize details on a total of 26 comparisons informed
by indirect evidence only.
Comparisons informed by indirect evidence only
1. Basic wound contact dressing compared with silver-
hydrofibre dressing.
2. Basic wound contact dressing compared with matrix-
hydrocolloid dressing.
3. Alginate dressing compared with hydrofibre dressing.
4. Alginate dressing compared with an iodine-impregnated
dressing.
5. Alginate dressing compared with hydrogel.
6. Alginate dressing compared with protease-modulating
matrix dressing.
7. Alginate dressing compared with matrix-hydrocolloid
dressing.
8. Foam dressing compared with hydrofibre dressing.
9. Foam dressing compared with iodine-impregnated dressing.
10. Foam dressing compared with hydrogel.
11. Foam dressing compared with a protease-modulating
matrix dressing.
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12. Foam dressing compared with silver-hydrofibre dressing.
13. Hydrofibre dressing compared with hydrogel.
14. Hydrofibre dressing compared with a protease-modulating
matrix dressing.
15. Hydrofibre dressing compared with silver-hydrofibre
dressing.
16. Hydrofibre dressing compared with matrix-hydrocolloid
dressing.
17. Iodine-impregnated dressing compared with hydrogel.
18. Iodine-impregnated dressing compared with a protease-
modulating matrix dressing.
19. Iodine-impregnated dressing compared with silver-
hydrofibre dressing.
20. Iodine-impregnated dressing compared with matrix-
hydrocolloid dressing.
21. Hydrogel compared with a protease-modulating matrix
dressing.
22. Hydrogel compared with silver-hydrofibre dressing.
23. Hydrogel compared with matrix-hydrocolloid dressing.
24. Protease-modulating matrix dressing compared with silver-
hydrofibre dressing.
25. Protease-modulating matrix dressing compared with
matrix-hydrocolloid dressing.
26. Silver-hydrofibre dressing compared with matrix-
hydrocolloid dressing.
An overview of comparisons in tabular format: Numbered com-
parisons refer to analyses based on direct comparison data alone
or direct plus indirect data.
Basic
dressing
Alginate Hydrogel Hydrofi-
bre
Iodine-
impreg-
nated
Foam Protease-
modulat-
ing matrix
Matrix-
hydrocol-
loid
Silver-
hydrofibre
Basic
dressing
Alginate Compari-
son 1
Hydrogel Compari-
son 2
Indirect
only
Hydrofi-
bre
Compari-
son 3
Indirect
only
Indirect
only
Hyalofill Compari-
son 4
Iodine-
impreg-
nated
Compari-
son 5
Indirect
only
Indirect
only
Compari-
son 10
Foam Compari-
son 6
Compari-
son 8
Indirect
only
Indirect
only
Indirect
only
Protease-
modulat-
ing matrix
Compari-
son 7
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Matrix-
hydrocol-
loid
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Compari-
son 9
Indirect
only
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(Continued)
Silver-
hydrofibre
Indirect
only
Compari-
son 11
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Indirect
only
Methodological quality of included reviews
We assessed the methodological quality of systematic reviews by
using the measurement tool AMSTAR; ratings for each systematic
review are presented in Table 3 for Cochrane reviews, and Table
4 for non-Cochrane reviews. Assessment was undertaken by team
members who were not authors on any included review.
All the Cochrane reviews received high AMSTAR scores (ranged
from 9 to 11), this could be as a result of following a generic
protocol specifyingmethods; while the non-Cochrane reviews also
scored in the medium to high range (from 7 to 10).
Effect of interventions
We present data for the 11 comparisons informed by direct evi-
dence from all reviews that included this comparison. In this way
we highlight overlap of evidence between reviews and also high-
light any differences in how data were reported between them.
Themajority of the comparisons that were informed by direct data
evaluated complete wound healing as the primary outcome.
When reporting the evidence for each comparison, we have
summarised the most complete and up-to-date data available.
We present data using the RR if available, if the RR was not
presented and could not be calculated we then present odds ratio
(OR) estimates or the alternative measures available. We report
95%confidence intervals (CI)where reported.One included study
reported 95% credible intervals (CrI), which we in turn report
here; these are the Bayesian equivalent of CIs.
It is important to note that the reviews by Dumville et al have very
consistent review protocols ( Dumville 2013a; Dumville 2013b;
Dumville 2013c; Dumville 2013d;Dumville 2012). For the out-
come number of ulcers/participants healed, these reviews treated
participants missing from the analyses as not having had a healed
wound. That is, the reviews made an assumption about missing
data such that the missing participants were included in the de-
nominator but not the numerator. Other reviews have conducted
analysis with complete case data. Discrepancies in effect estimates
may have resulted from these differences, and these have been
flagged in the tables of extracted data that accompany each com-
parison below.
Comparison 1: basic wound contact dressing
compared with alginate dressing
All extracted data reported in Table 5
Review ID Cochrane review? AMSTAR Score Included studies relevant to this comparison
Donaghue 1998; n =
75
8-week follow-up
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear
Risk of detection bias:
unclear
Risk of attrition bias:
low
Lalau 2002; n = 77
6-week follow-up
Complete wound
healing data reported?
No
Risk of selection bias:
unclear
Risk of detection bias:
low
Risk of attrition bias:
high
Ahroni 1993; n = 39
4-week follow-up
(unclear if longer)
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear
Risk of detection bias:
high
Risk of attrition bias:
low
Dumville 2013a Yes 10
√ √ √
Dumville 2012 No 9
√ √
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(Continued)
Hinchliffe 2008b No 7
√ √
O’Meara 2000 No 9
√
Mason 1999a No 7
√ √
Direct data: complete wound healing
Two reviews (Dumville 2013a; Dumville 2012) pooled complete
wound healing data from two studies (Donaghue 1998; Ahroni
1993; n = 114) that reported number of wounds healed over their
six- and four-week follow-up times. In total 51% (36/70) of ulcers
in the alginate group healed and 53% (23/44) of ulcers in the basic
wound contact dressing group healed: RR 1.09, 95% CI 0.66 to
1.80 (fixed-effect model; I² 27%). The direct estimate was classed
as being of moderate quality using the GRADE assessment (Dumville
2012).
Direct and indirect data: complete wound healing
Whendirect and indirect datawere considered for this comparison
there was no evidence of a difference in the number of ulcers healed
in the alginate group compared with the basic wound contact
dressing group: OR 1.29, 95% CrI 0.57 to 2.51 (Dumville 2012).
The study authors used an ad hoc method to assess the quality of
the mixed treatment comparison outputs: this estimate was classed
as being of moderate quality.
Direct data: secondary outcomes
Limited secondary outcomes were reported: Dumville 2013a
noted that theDonaghue 1998 study reported six trial participants
with adverse events, but it was not clear to which groups these
participants belonged, and the adverse events were not described.
The same review noted that Ahroni 1993 reported two amputa-
tions in each trial group along with six additional adverse events
for the alginate-dressed group and four in the basic wound contact
dressing group.
Summary of findings: alginate dressing versus basic wound
contact dressing
Data from two studies (pooled in two reviews) consistently suggest
there is no evidence of a difference in ulcer healing between al-
ginate and basic wound contact dressings. There was imprecision
in estimates so that a difference favouring either alginate dressings
or basic wound contact dressings cannot be ruled out. There are
limited data available on other outcomes for this comparison.
Comparison 2: basic wound contact dressing
compared with hydrogel
All extracted data reported in Table 6
Review ID Cochrane review? AMSTAR Score Included studies relevant to this comparison
D’Hemecourt 1998;
n = 138
20-week follow-up
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear
Risk of detection bias:
unclear
Risk of attrition bias:
low
Jensen 1998: n= 31
16-week follow-up
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear
Risk of detection bias:
unclear
Risk of attrition bias:
unclear
Vandeputte 1997: n =
29
12-week
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear
Risk of detection bias:
unclear
Risk of attrition bias:
unclear
Dumville 2013d Yes 10
√ √ √
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Dumville 2012 No 9
√ √ √
Edwards 2010 Yes 9
√ √ √
Hinchliffe 2008b No 7
√
Nelson 2006 No 7
√
Direct data: complete wound healing
Three reviews (Dumville 2013d; Dumville 2012; Edwards 2010)
pooled data from the same three studies (198 participants), which
had follow-up times of 20, 16 and 12 weeks. Overall 85% (50/
99) of ulcers in the hydrogel group healed (the Edwards 2010
review reported 51/99 for this group) and 28% (28/99) of ulcers
in the basic wound contact group healed: RR 1.80, 95% CI 1.27
to 2.56 (fixed-effect model; I² 0%) reported for Dumville 2013d,
and RR 1.84, 95% CI 1.30 to 2.61(fixed-effect model: I² 0%)
reported by Edwards 2010. This suggests some evidence of an
increase in the number of wounds healed in the hydrogel-treated
group, however the direct estimate was classed as being of low quality
using the GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
Whendirect and indirect datawere considered for this comparison
there was evidence of an increase in the number of ulcers healed
in the hydrogel group compared with the basic wound contact
dressing group: OR 3.10, 95% CrI 1.51 to 5.50 (Dumville 2012).
The study authors used an ad hoc method to assess the quality of
the mixed treatment comparison outputs: this estimate was classed
as being of very low quality.
Direct data: secondary outcomes
Dumville 2013d and Edwards 2010 summarised available data
on adverse events, pain and infection from the three relevant tri-
als. The Dumville 2013d review did not pool data, citing lack of
methodological information on data collection methods for these
outcomes. Edwards 2010 reported a total of 22 complications/
events in the hydrogel groups, compared with 36 events in the
comparison groups. These review authors pooled these trials sug-
gesting evidence of an increase in adverse events/complications in
the basic wound contact dressing group: RR 0.60, 95%CI 0.38 to
0.95 (fixed-effect model; I² 31%). When a random-effects model
was applied, however, there was no longer evidence of a difference
between groups: RR 0.56, 95% CI 0.25 to 1.25.
Summary of findings: hydrogel dressing versus basic wound
contact dressing
Three recent reviews drew on the same three studies and reported
evidence of an increase in the number of wounds that healed when
treated with hydrogel compared with basic wound contact dress-
ings, although this is judged as being low quality evidence. Het-
erogeneity in the data for adverse events means that the impact of
hydrogel on these is unclear. The overall impact of hydrogel on
ulcers is uncertain due to the low quality of the evidence.
Comparison 3: basic wound contact dressing
compared with hydrofibre dressing
All extracted data reported in Table 7
Review ID Cochrane review? AMSTAR Score Included studies relevant to this comparison
Piaggesi 2001; n = 20
Max 350 days follow-up
Complete wound healing data re-
ported? Yes
Risk of selection bias: unclear
Risk of detection bias:unclear
Risk of attrition bias: low
Jeffcoate 2009: n = 209
24-week follow-up
Complete wound healing data re-
ported? Yes
Risk of selection bias: low
Risk of detection bias:low
Risk of attrition bias: unclear
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Dumville 2013b Yes 10
√ √
Dumville 2012 No 9
√ √
Game 2012 No 7
√
Hinchliffe 2008b No 7
√
Direct data: complete wound healing
Two reviews pooled data from two RCTs (n = 229) with 24-week
and 350-day follow-up respectively (Dumville 2013b; Dumville
2012). There was no evidence of a difference in the number of
ulcers healed between the hydrofibre and the basic wound con-
tact dressing treated groups with 49% (55/113) of ulcers in the
hydrofibre group healed and 44% (51/116) of ulcers in the basic
wound contact group healed: RR 1.01, 95%CI:0.74 to 1.38 (ran-
dom-effects model; I² 54%: Dumville 2013b; Dumville 2012).
The direct estimate was classed as being of moderate quality using the
GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
When direct and indirect data were considered for this compar-
ison, again there was no evidence of a difference in the number
of ulcers healed in the hydrofibre group compared with the basic
wound contact group: OR 1.28, 95% CrI 0.71 to 2.13 (Dumville
2012). The study authors used an ad hoc method to assess the
quality of the mixed treatment comparison outputs: this estimate
was classed as being of moderate quality.
Direct data: secondary outcomes
Two reviews, Dumville 2013b and Game 2012, reported cost
data from one study, Jeffcoate 2009, that suggested that the ba-
sic wound contact dressing was considered to be a more cost-ef-
fective treatment than the hydrofibre dressing with the difference
largely driven by the higher dressing costs in the hydrofibre group.
Dumville 2013b reported data on the number of serious and non
serious adverse events, summarising no evidence of a difference
in these, nor in measures of health-related quality of life, between
the two groups. Game 2012 reported the number of secondary
infections for the Jeffcoate 2009 study’s three arms (also see com-
parison 5 and 10) alongside an overall P value of < 0.001 for the
three-way comparison (but did not specify which dressing(s) were
superior). Further information was not presented on these data,
but the review concluded, in contrast to the data presented, that
there was no evidence of a difference in the incidence of secondary
infection. Returning to the original study, Jeffcoate 2009, we con-
firmed that this is what the trial also concluded after a full analysis
of the data, including the numbers of withdrawals and adjustment
for the number of dressing changes.
Summary of findings: hydrofibre dressing versus basic
wound contact dressing
Two recent reviews including data from two studies reported no
evidence of a difference in the number of ulcers healed in hydrofi-
bre and basic wound contact groups. The 95% CIs were wide and
did not rule out an effect in either direction. Both reviews also
reported the finding from one included study that basic wound
contact dressings were a more cost-effective treatment than hy-
drofibre dressing. One review reported no evidence of a difference
in the number of serious and non serious events between groups,
and one review reported no evidence of a difference in the num-
ber of secondary infections between hydrofibre and basic wound
contact treated wounds.
Comparison 4: basic wound contact dressing
compared with Hyalofill® dressing
All extracted data reported in Table 8
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Review ID Cochrane review? AMSTAR Score Included studies
Edmonds 2000; n = 30
12-week follow-up
Complete wound healing data reported? Yes
Risk of selection bias: not clear from review
Risk of detection bias:not clear from review
Risk of attrition bias: not clear from review
Voigt 2012 No 10
√
Direct data: complete wound healing
One review, Voigt 2012, reported data from one small study (30
participants) with a 12-week follow-up. There was evidence that
more ulcers healed when allocated to Hyalofill® (a hyaluronic fi-
brous dressing) 67% (10/15) than to a basic wound contact dress-
ing 20% (3/15); RR: 0.26, 95% CI 0.12 to 0.53. The risk of bias
for this study was not clearly reported in the review. We examined
the primary study, Edmonds 2000, but were unable to source the
data that were reported in the review.
Direct and indirect data: complete wound healing
Not available from Dumville 2012.
Direct data: secondary outcomes
No relevant secondary outcomes from this trial were reported in
this review.
Summary of findings: basic wound contact dressing versus
Hyalofill®
One review included a single study and reported that more ulcers
healed when treated with a Hyalofill® dressing compared with a
basic wound contact dressing. Presentation of risk of bias/study
quality was not included in the review and the original data could
not be located in the referenced primary source. The estimate
was also based on a single small trial, meaning that the difference
reported could have occurred as a result of chance.
Comparison 5: basic wound contact dressing
compared with iodine-impregnated dressing
All extracted data reported in Table 9
Review ID Cochrane review? AMSTAR Score Included studies
Jeffcoate 2009; n = 214
24-week follow-up
Complete wound healing data reported? Yes
Risk of selection bias: low risk
Risk of detection bias:low risk
Risk of attrition bias: unclear risk
Dumville 2012 No 9
√
Game 2012 No 7
√
Direct data: complete wound healing
Two systematic reviews,Dumville 2012 andGame 2012, included
data from one study (214 participants) that compared a basic
wound contact dressing with an iodine-impregnated dressing. The
same trial data were reported in these two reviews. There was no
evidence of difference in complete wound healing between the
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iodine-impregnated dressing group 44% (48/108) and the basic
wound contact dressing group 39% (41/106). Summary data were
available from only Dumville 2012, which reported OR: 1.27,
95% CrI: 0.74 to 2.19: the direct estimate was classed as being of
moderate quality using the GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
When direct and indirect data were considered for this compari-
son, again there was no evidence of a difference in the number of
ulcers healed in the iodine-impregnated group compared with the
basic wound contact dressing group: OR 1.28, 95% CrI 0.71 to
2.13 (Dumville 2012). The study authors used an ad hoc method
to assess the quality of the mixed treatment comparison outputs:
this estimate was classed as being of moderate quality.
Direct data: secondary outcomes
OnlyGame 2012 reported secondary outcomes from the included
study.Game2012 reported the number of secondary infections for
the Jeffcoate 2009 study’s three arms (also see comparisons 3 and
10) alongside a single P value of < 0.001. Further information was
not presented on these data, but the review concluded, in contrast
to the data presented, that there was no evidence of a difference
in the incidence of secondary infection. Returning to the original
study, Jeffcoate 2009, we confirmed that this was what the trial
also concluded after in-depth analyses.
Summary of findings: basic wound contact dressing versus
iodine dressing
Two reviews summarised data from a single trial.Moderate quality
data suggest no evidence of a difference in the number of ulcers
healed between the basic wound contact dressing and the iodine-
impregnated dressing groups. However, the estimates are uncer-
tain and the comparison potentially underpowered. There was no
evidence of a difference in the number of adverse events, including
secondary infections, between groups.
Comparison 6: basic wound contact dressing
compared with foam dressing
All extracted data reported in Table 10
Review ID Cochrane review? AMSTAR Score Included studies
Blackman 1994; n =
18
Follow-up:until heal-
ing or 6months (some
reviews only
extract 2-month heal-
ing data due to treat-
ment cross-over fol-
lowing this point)
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear risk
Risk of detection bias:
unclear risk
Risk of attrition bias:
unclear risk
Mazzone 1993; n = 19
8-week follow-up
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear risk
Risk of detection bias:
unclear risk
Risk of attrition bias:
unclear risk
Roberts 2001; n = 30
13-week follow-up
Complete wound
healing data reported?
Yes
Risk of selection bias:
unclear risk
Risk of detection bias:
unclear risk
Risk of attrition bias:
unclear risk
Dumville 2013c Yes 10
√ √ √
Dumville 2012 No 9
√ √ √
Hinchliffe 2008b No 7
√
O’Meara 2000 No 9
√
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Mason 1999a No 7
√
Direct data: complete wound healing
Two reviews, Dumville 2013c and Dumville 2012, included data
from three studies (67 participants) that had follow-up ranging
from eight to 13 weeks. Three older reviews with data on this
comparison included only one study. The authors of Dumville
2013c noted they were unclear whether two of the included stud-
ies, Mazzone 1993 and Blackman 1994, were reports of the same
study, and presented pooled data for only two studies. There was
no clear evidence of a difference in the number of ulcers healed
with 52% (13/25) healed in the foam dressing group and 33% (8/
24) healed in the basic wound contact dressing group: RR 2.03,
95% CI:0.91 to 4.55 (fixed-effect model; I² 0%). The direct esti-
mate was classed as being of low quality using the GRADE assessment
(Dumville 2012).
Direct and indirect data: complete wound healing
Whendirect and indirect datawere considered for this comparison
there was evidence of a greater number of ulcers healed in the foam
dressing group compared with the basic wound contact dressing
group: OR 4.32, 95% CrI 1.56 to 9.85 (Dumville 2012). The
study authors used an ad hoc method to assess the quality of the
mixed treatment comparison outputs: this estimate was classed as
being of very low quality
Direct data: secondary outcomes
Data on secondary outcomes were limited; there were no data on
cost, health-related quality of life or adverse events available from
the trial reports (Dumville 2013c).
Summary of findings: basic wound contact dressing versus
foam dressing
Data from the two studies with direct comparisons showed no
evidence of a different in ulcer healing between foam dressing
and basic wound contact dressing-treated groups. An estimate that
included indirect as well as direct comparisons, and which was
classed as being of very low quality found that more ulcers healed
when treated with foam dressings than with basic wound contact
dressings. There were limited data available on other outcomes.
Data were very uncertain and were of low or very low quality.
Comparison 7: basic wound contact dressing
compared with protease-modulating matrix dressing
All extracted data reported in Table 11
Review ID Cochrane review? AMSTAR Score Included studies
Veves 2002; n = 276
12-week follow-up
Complete wound healing data reported? Yes
Risk of selection bias: unclear
Risk of detection bias:unclear
Risk of attrition bias: Uncear
Dumville 2012 No 9
√
Direct data: complete wound healing
Data from one study for this comparison was included in one re-
view we identified (Dumville 2012). There was no evidence of a
difference in complete wound healing between protease-modulat-
ing matrix-treated and basic wound contact dressing treated par-
ticipants with 37% (51/138) healed in the protease-treated group
and 28% (39/138) in the basic wound contact dressing group: OR
1.49, 95% CI 0.90 to 2.47. The direct estimate was classed as being
of moderate quality using the GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
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Dumville 2012 also reported the effectiveness estimate from the
mixed treatment comparison. Again, there was no evidence of a
different between the dressing groups: OR 1.54, 95% CrI 0.89
to 2.47. The study authors used an ad hoc method to assess the
quality of the mixed treatment comparison outputs: this estimate
was classed as being of moderate quality
Direct data: secondary outcomes
The review reported no data on secondary outcomes.
Summary of findings: basic wound contact dressing versus
protease-modulating matrix dressing
Data from one study reported no evidence of a difference in ulcer
healing between protease-modulating matrix dressing- and basic
wound contact dressing-treated groups. There were limited data
available on other outcomes. Data were judged as being of mod-
erate quality, however, estimates were uncertain with the 95% CI
favouring both treatments.
Comparison 8: foam dressings compared with
alginate dressing
All extracted data reported in Table 12
Review ID Cochrane review? AMSTAR Score Included studies
Baker 1993; n = 20,1 review pre-
sented data on 19 participants)
12-week follow-up or until ulcer
healed
Complete wound healing data re-
ported? Yes
Risk of selection bias: unclear risk
Risk of detection bias:unclear risk
Risk of attrition bias: unclear risk
Foster 1994; n = 30
8-week follow-up or until ulcer
healed
Complete wound healing data re-
ported? Yes
Risk of selection bias: unclear risk
Risk of detection bias:unclear risk
Risk of attrition bias: unclear risk
Dumville 2013c Yes 10
√ √
Dumville 2013a Yes 10
√ √
Dumville 2012 No 9
√ √
O’Meara 2000 No 9
√ √
Mason 1999a No 7
√
Direct data: complete wound healing
All five reviews reported no clear evidence of a difference in the
number of ulcers healed in the foam dressing group compared
with the alginate dressing group. Three reviews, Dumville 2013c,
Dumville 2013a andDumville 2012, pooled data from two studies
(with a total of 50 participants although 1 review, O’Meara 2000,
presented data on 49 not 50 participants) with 72% (18/25) of
ulcers in the foam group healed and 56% (14/25) of ulcers in
the alginate group healed: RR 1.50, 95% CI 0.92 to 2.44 (fixed-
effect model; I² 45%). The direct estimate was classed as being of
low quality using the GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
Dumville 2012 also reported the effectiveness estimate from the
mixed treatment comparison. Here there was evidence of a differ-
ence between the dressing groups that favoured foam dressings:
OR 3.61, 95%CrI 1.30 to 8.30. The study authors used an ad hoc
method to assess the quality of the mixed treatment comparison
outputs: this estimate was classed as being of very low quality.
Direct data: secondary outcomes
Dumville 2013a reported that one trial, Foster 1994, noted no
adverse events for the foam group compared with four events for
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the alginate group (severe pain: 1; plugging of plantar lesion block-
ing drainage: 3). No other relevant secondary outcomes were pre-
sented.
Summary of findings: foam dressing versus alginate dressing
Overall data across four systematic reviews reported no clear ev-
idence of a difference between these dressings, although an esti-
mate based on indirect as well as direct evidence found that more
wounds healed with foam dressings than with alginate dressings.
Estimates were very uncertain and imprecise.
Comparison 9: foam dressing compared with matrix-
hydrocolloid dressing
All extracted data reported in Table 13
Review ID Cochrane review? AMSTAR Score Included studies
Clever 1995; n = 40
16-week follow-up maximum
Complete wound healing data reported? Yes
Risk of selection bias: unclear risk
Risk of detection bias:unclear risk
Risk of attrition bias: high risk
Dumville 2013c Yes 10
√
Dumville 2013b Yes 10
√
Dumville 2012 No 9
√
O’Meara 2000 No 9
√
Mason 1999a No 7
√
Direct data: complete wound healing
Five reviews (Dumville 2013c; Dumville 2013b; Dumville 2012;
O’Meara 2000; Mason 1999a) included the same data from one
study for this comparison: (n = 40) with a 16-week follow-up.
There was no evidence of a difference in the number of ulcers
healed between the foam dressing 70% (14/20) and the matrix-
hydrocolloid dressing 80% (16/20) treated groups: RR 0.88, 95%
CI 0.61 to 1.26. The direct estimate was classed as being of low
quality using the GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
Dumville 2012 also reported the effectiveness estimate from the
mixed treatment comparison. Again there was no evidence of a
different between the dressing groups: OR 2.40, 95% CrI 0.40 to
8.40.The study authors used an adhocmethod to assess the quality
of the mixed treatment comparison outputs for this comparison:
this estimate was classed as being of very low quality.
Direct data: secondary outcomes
Data on secondary outcomes were limited; Dumville 2013b re-
ported five adverse events in the foam dressing group and one in
the matrix-hydrocolloid dressing group. Details of adverse event
data collection methods were limited. The mean number of dress-
ing changes between clinical visits was similar for both groups.
Summary of findings foam dressing compared with matrix-
hydrocolloid
Data across five systematic reviews consistently reported no evi-
dence of a difference between these dressings. Estimates were very
uncertain, as studies were small and underpowered.
Comparison 10: iodine-impregnated dressing
compared with hydrofibre dressing
All extracted data reported in Table 14
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Review ID Cochrane review? AMSTAR Score Included studies
Jeffcoate 2009; n = 211
24-week follow-up
Complete wound healing data reported? Yes
Risk of selection bias: unclear
Risk of detection bias:low risk
Risk of attrition bias: low risk
Dumville 2013b Yes 10
√
Dumville 2012 No 9
√
Game 2012 No 7
√
Direct data: complete wound healing
Three reviews. Dumville 2013b, Dumville 2012 and Game 2012,
included data from one study (211 participants) with 24-week fol-
low-up. Data from this study suggested no evidence of a difference
in the number of ulcers healed in the iodine-impregnated dress-
ing group 44% (48/108) compared with the hydrofibre dressing
group 39% (46/103): RR 1.00, 95% CI 0.74 to 1.34. The direct
estimate was classed as being of moderate quality using the GRADE
assessment (Dumville 2012).
Direct and indirect data: complete wound healing
Dumville 2012 also reported the effectiveness estimate from the
mixed treatment comparison. There was again no evidence of a
different between the dressing groups: OR 1.05, 95% CrI 0.99
to 1.75. The study authors used an ad hoc method to assess the
quality of the mixed treatment comparison: the estimate was classed
as being of moderate quality.
Direct data: secondary outcomes
Both reviews which assessed this (Dumville 2013b, Game 2012)
concluded that the costs of using fibrous-hydrocolloid and an io-
dine-impregnated dressing were similar, although there was wide
imprecision around the estimates. There was no evidence of a dif-
ference in the number of adverse events, or health-related quality
of life.
Summary of findings: iodine dressing versus hydrofibre
dressing
Data from three reviews reporting one relevant included study for
this comparison consistently reported no evidence of a difference
between these dressings in terms of healing, adverse events, or
quality of life.
Comparison 11: alginate compared with silver-
hydrofibre dressing
All extracted data reported in Table 15
Review ID Cochrane review? AMSTAR Score Included studies
Jude 2007; n = 134
8-week follow-up
Complete wound healing data reported? Yes
Risk of selection bias: unclear risk
Risk of detection bias:unclear risk
Risk of attrition bias: low risk
Dumville 2013a No 10
√
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Dumville 2012 Yes 9
√
Game 2012 No 7
√
Storm-Versloot 2010 Yes 11
√
Direct data: complete wound healing
Four systematic reviews included data from the same study, which
had 134 participants and an eight-week follow-up. There was no
evidence of a difference in the number of ulcers healed in the
silver-hydrofibre group 31% (21/67) compared with the alginate
dressing group 22% (15/67): RR 1.40, 95% CI 0.79 to 2.47.
The direct estimate was classed as being of moderate quality using the
GRADE assessment (Dumville 2012).
Direct and indirect data: complete wound healing
Dumville 2012 also reported the effectiveness estimate from the
mixed treatment comparison. Again, there was no evidence of a
different between the dressing groups: OR 1.73, 95% CrI 0.73
to 3.53. The study authors used an ad hoc method to assess the
quality of the mixed treatment comparison outputs: this estimate
was classed as being of moderate quality.
Direct data: secondary outcomes
There did not appear to be any difference in the number of adverse
events, time to healing ormean number of dressing changes during
the study in the silver-hydrofibre-dressed group and the alginate-
dressed group. There were more infections (type unclear) in the
silver-hydrofibre group (14 versus 8).
Summary of findings: alginate versus silver-hydrofibre
dressing
Data from four reviews reporting one relevant included study for
this comparison consistently reported no evidence of a difference
between these dressings. Estimates were very uncertain as the study
was relatively small and underpowered.
Summary of all findings informed by direct data
Complete wound healing
Direct data
Complete wound healing
Direct and indirect data
Secondary outcomes
Direct data
1. Basic wound contact dress-
ing compared with alginate
dressings
Data from two trials (n = 114)
. Short term follow-up times (4
and 8 weeks)
No evidence of a difference in
complete wound healing
RR 1.09, 95% CI 0.66 to 1.80
Moderate quality evidence
No evidence of a difference in
complete wound healing
OR 1.29, 95% CrI 0.57 to 2.
51
Moderate quality evidence
Limited data available, no ev-
idence in either direction pre-
sented
2. Basic wound contact dress-
ing compared with hydrogel
dressings
Data from three trials (n = 198)
Short- and medium-term fol-
low-up times (4, 16 and 20
weeks)
Evidence of a more complete
wound healing with hydrogel
RR 1.80, 95% CI: 1.27 to 2.56
Low quality evidence
Evidence of more complete
wound healing with hydrogel
OR 3.10, 95% CrI 1.51 to 5.
50
Very low quality evidence
One review pooled adverse
event data, reporting no evi-
dence of a different in adverse
events when a random-effects
model was used. RR 0.56, 95%
CI 0.25 to 1.25
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3. Basic wound contact dress-
ing compared with hydrofibre
dressing
Data from two trials (n = 229).
Medium-term follow-up of 24
weeks/up to 350 days
No evidence of a difference in
complete wound healing
RR 1.01, 95% CI: 0.74 to 1.38
Moderate quality evidence
No evidence of a difference in
complete wound healing
OR 1.28, 95% CrI 0.71 to 2.
13
Moderate quality evidence
Some evidence that hydrofibre
was not a cost-effective treat-
ment. No evidence of a differ-
ence in secondary outcomes in-
cluding adverse events
4. Basic wound contact dress-
ing compared with
Hyalofill® dressing
Data from one study (n = 30).
Medium-term follow-up of 12
weeks
Evidence of an increase in
complete wound healing with
Hyalofill®
RR 0.26, 95% CI 0.12 to 0.53
No further information avail-
able. Unable to locate data in
cited source.
Not reported Not reported
5. Basic wound contact dress-
ing comparedwith iodine-im-
pregnated dressing
Data from one trial (n = 214).
Medium-term follow-up of 24
weeks
No evidence of a difference in
complete wound healing
OR 1.27, 95% CrI 0.74 to 2.
19
Moderate quality evidence
No evidence of a difference in
complete wound healing
OR 1.28, 95% CrI 0.71 to 2.
13
Moderate quality evidence
No evidence of a different in
secondary outcomes including
adverse events
6. Basic wound contact dress-
ing compared with foam
dressing
Data from two trials (n = 49)
Medium-term follow-up of 8
and 13 weeks
No clear evidence of a differ-
ence in complete wound heal-
ing
RR 2.03, 95% CI 0.91 to 4.55
Low quality evidence
Evidence of an increase in
complete wound healing with
foam
OR 4.32, 95% CrI 1.56 to 9.
85
Very low quality evidence
Limited data available, no ev-
idence in either direction pre-
sented
7. Basic wound contact dress-
ing compared with protease-
modulating matrix dressing
Data from 1 trial (n = 276).
Medium-term follow-up of 12
weeks
No clear evidence of a differ-
ence in complete wound heal-
ing
OR 1.49, 95% CrIs 0.90 to 2.
47
Moderate quality evidence
No evidence of a difference in
complete wound healing
OR 1.54, 95% CrI 0.89 to 2.
47
Moderate quality evidence
Not reported
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8. Foam dressings compared
with alginate dressing
Data from 2 trials (n = 50).
Medium-term follow-up of 8
and 12 weeks
No evidence of a difference in
complete wound healing
RR 1.50, 95% CI 0.92 to 2.44
Low quality evidence
Evidence of an increase in
complete wound healing with
foam
OR 3.61, 95% CrI 1.30 to 8.
30
Very low quality evidence
Limited data available, no ev-
idence in either direction pre-
sented
9. Foam dressing
compared with matrix-hydro-
colloid dressing
Data from 1 trial (n = 40).
Medium-term follow-up of 16
weeks
No evidence of a difference in
complete wound healing
RR 0.88, 95% CI 0.61 to 1.26
Low quality evidence
No clear evidence of a differ-
ence in complete wound heal-
ing
OR 2.40, 95% CrI 0.40 to 8.
40
Very low quality evidence
Limited data available, no ev-
idence in either direction pre-
sented
10. Iodine-im-
pregnated dressing compared
with hydrofibre dressing
Data from 1 trial (n = 211).
Medium-term follow-up of 24
weeks
No evidence of a difference in
complete wound healing
RR 1.00, 95% CI 0.74 to 1.34
Moderate quality evidence
No evidence of a difference in
complete wound healing
OR 1.05, 95% CrI 0.99 to 1.
75
Moderate quality evidence
No evidence of a difference in
secondary outcomes including
adverse events
11. Alginate compared with
silver-hydrofibre dressing
Data from 1 trial (n = 134)
. Short-term follow-up of 8
weeks
No clear evidence of a differ-
ence in complete wound heal-
ing
RR 1.73, 95% CI 0.73 to 3.53
Moderate quality evidence
No clear evidence of a differ-
ence in complete wound heal-
ing
OR 1.73, 95% CrI 0.73 to 3.
53
Moderate quality evidence
No evidence of a difference in
adverse events or number of
dressing changes, no health-re-
lated quality of life data
Comparisons informed by indirect evidence only (from
Dumville 2012). The favoured intervention is in bold (OR > 1
favour the second intervention listed and OR < 1 favour the
first listed).
Comparison OR (95% CrI) Quality of estimate assessment
Basic wound contact dressing compared
with silver-hydrofibre dressing
2.22 (0.65 to 5.60) Very low quality evidence
Basic wound contact dressing compared
with matrix-hydrocolloid dressing
10.38 (1.19 to 42.1) Very low quality evidence
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Alginate dressing compared with hydrofi-
bre dressing
1.15 (0.41 to 2.57) Low quality evidence
Alginate dressing compared with an io-
dine-impregnated dressing
1.16 (0.42 to 2.60) Low quality evidence
Alginate dressing compared with hydrogel 2.99 (0.98 to 7.12) Very low quality evidence
Alginate dressing compared with protease-
modulating matrix dressing
1.38 (0.51 to 3.05) Very low quality evidence
Alginate dressing compared with matrix-
hydrocolloid dressing
8.66 (1.02 to 34.71) Very low quality evidence
Foam dressing compared with hydrofibre
dressing
0.37 (0.11 to 0.93) Moderate quality evidence
Foam dressing compared with iodine-im-
pregnated dressing
0.37 (0.11 to 0.93) Moderate quality evidence
Foam dressing compared with hydrogel 0.96 (0.26 to 2.53) Very low quality evidence
Foam dressing compared with a protease-
modulating matrix dressing
0.45 (0.13 to 1.10) Moderate quality evidence
Foam dressing compared with silver-hy-
drofibre dressing
0.60 (0.15 to 1.66) Moderate quality evidence
Hydrofibre dressing comparedwith hydro-
gel
2.81 (1.10 to 6.00) Very low quality evidence
Hydrofibre dressing compared with a pro-
tease-modulating matrix dressing
1.30 (0.57 to 2.57) Moderate quality evidence
Hydrofibre dressing compared with silver-
hydrofibre dressing
1.88 (0.46 to 5.27) Low quality evidence
Hydrofibre dressing compared with ma-
trix-hydrocolloid dressing
8.81 (0.88 to 37.8) Very low quality evidence
Iodine-impregnated dressing compared
with hydrogel
2.79 (1.09 to 6.00) Very low quality evidence
Iodine-impregnated dressing compared
with aprotease-modulatingmatrix dress-
ing
1.29 (0.57 to 2.53) Moderate quality evidence
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Iodine-impregnated dressing compared
with silver-hydrofibre dressing
1.86 (0.46 to 5.22) Low quality evidence
Iodine-impregnated dressing compared
with matrix-hydrocolloid dressing
8.72 (0.87 to 37.3) Very low quality evidence
Hydrogel compared with a protease-mod-
ulating matrix dressing
0.52 (0.20 to 1.08) Low quality evidence
Hydrogel compared with silver-hydrofibre
dressing
0.75 (0.17 to 2.16) Low quality evidence
Hydrogel compared with matrix-hydro-
colloid dressing
3.47 (0.33 to 14.7) Very low quality evidence
Protease-modulating matrix dressing com-
pared with silver-hydrofibre dressing
1.55 (0.39 to 4.31) Low quality evidence
Protease-modulating matrix dressing com-
pared with matrix-hydrocolloid dressing
7.24 (0.75 to 30.5) Very low quality evidence
Silver-hydrofibre dressing compared with
matrix-hydrocolloid dressing
5.88 (0.53 to 26.2) Very low quality evidence
D I S C U S S I O N
Summary of main results
This overview of reviews identified 13 eligible reviews for inclu-
sion; six were Cochrane reviews and seven were non-Cochrane
reviews. One of the non-Cochrane reviews reported the results of
a network meta-analysis, the results of which are reported here.
Eleven comparisons were informed by direct data; with 10 of these
also informed by direct and indirect data from the network meta-
analysis. Many of the reviews reported similar comparisons with,
as one would expect, more trials included in the more recent re-
views. All included reviews were deemed to be of moderate to
high quality. For comparisons informed in part by direct data
the reviews reported no clear evidence of a difference between
the following dressings in terms of wound healing:
1. basic wound contact dressing compared with alginate
dressings (moderate quality evidence);
2. basic wound dressing compared with hydrofibre dressing
(moderate quality evidence);
3. basic wound contact dressing compared with iodine-
impregnated dressing (moderate quality evidence);
4. basic wound contact dressing compared with protease-
modulating matrix dressing (moderate quality evidence);
5. foam dressing compared with matrix-hydrocolloid dressing
(low quality evidence);
6. iodine-impregnated dressing compared with hydrofibre
dressing (moderate quality evidence);
7. alginate compared with silver-hydrofibre dressing
(moderate quality evidence).
Evidence of a difference in wound healing between dressings
was reported for the following (favoured intervention in bold):
1. basic wound contact dressing compared with hydrogel
dressings (low/very low quality evidence);
2. basic wound contact dressing compared with foam
dressing (very low quality evidence);
3. foam dressings compared with alginate dressing (direct and
indirect data only - very low quality evidence);
4. basic wound contact dressing compared with Hyalofill
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dressing, but data could not be obtained for the reference and
we were unable to assess the original data.
There is currently no robust evidence that any ’advanced’ dress-
ings type is more effective than basic wound contact dressings for
healing foot ulcers in people with diabetes mellitus (DM). There
was imprecision around the estimates for all these comparisons,
as small numbers of trials were available - the maximum num-
ber of randomised controlled trials (RCTs) per comparison was
three - and these trials had generally small numbers of partici-
pants, therefore the potential effectiveness of the treatments re-
mains uncertain. In the three comparisons where direct evidence
of differences was reported the evidence was deemed to be low or
very low quality, and in one case could not be assessed, therefore
these findings are not optimal in terms of informing practice and
are also considered uncertain. The small size of the evidence base
represented in this overview was also evident in the large amount
of imprecision around all estimates informed only by indirect data
that were reported by the network meta-analysis included in the
review.
This overview evaluated a number of different dressing types, in-
cluding basic wound contact, hydrogel, hydrocolloid, foam, algi-
nate, protease-modulating and antimicrobial (iodine and silver).
It has been suggested that different dressings may be targeted to
manage specific wound states or stages of healing (Boateng 2008),
implying that complete healing may not be an appropriate treat-
ment aim for all interventions. For example, foam and alginate
products may be used to manage periods of heavy exudate, whilst
antimicrobial dressings should be applied in order to resolve in-
fection (BNF 2014). The implication is that such products are
designed to create an optimal environment for a wound healing
trajectory, but would not necessarily be expected to achieve healing
directly. Specific guidance on this aspect of wound management is
not easily gleaned from the literature (Boateng 2008); this also has
an impact on clinical guidelines, as it means that clear recommen-
dations on dressing choice are difficult to define (NICE 2013).
However, prescribing guidelines and some local clinical practice
guidelines attempt to provide support for clinical decision mak-
ing (BNF 2014; Leeds Community Healthcare 2011). Most of
the RCTs discussed in this overview focused on wound healing
as the primary outcome and presented relatively sparse data on
secondary outcomes (e.g. exudate management). More research is
needed into the nature of benefits that may be achieved with dif-
ferent types of dressings and how additional outcomes of impor-
tance to decision makers (including service users) such as exudate
management, resolution of infection and adverse effects may best
be measured.
Quality of the evidence
In general all of the included reviews were of moderate to high
quality as assessed using AMSTAR, which is the recommended
approach for Cochrane overviews of reviews. As one might expect,
the Cochrane reviews had the highest scores as they all followed
a similar and prescribed process. All reviews point to the limited
number of studies that address the review question. Furthermore
the available studies were often small and probably underpowered.
Additionally studies seldom made use of optimal outcomes such
as time to healing and rarely reported secondary outcome data in a
clear and consistent manner. We also acknowledge the limitations
associated with the size of the available evidence base for several
included comparisons, with many having only a single identified
trial.
Potential biases in the overview process
We followed a rigorous review process aiming to minimise bias
at all stages. We do note that one of the overview authors was
also an author on five of the reviews included here. This author
was not involved in the quality assessment of reviews nor in data
extraction.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no robust evidence of differences between
wound dressings for any outcome in foot ulcers in people with
diabetes (treated in any setting). When choosing dressings, prac-
titioners may want to consider the unit cost of dressings, together
with their management properties and patient preference.
Implications for research
There is uncertainty about the use of different types of dressings
to treat foot ulcers in diabetes that could be reduced with further
research. However, such research would be costly so it is impor-
tant to assess the value of further research and whether resolving
uncertainty in this area is a priority for patients and clinical deci-
sion makers. Other possible topics for research related to this topic
include exploring whether non-healing outcomes are important
to health professionals and patients, and how these could be mea-
sured.
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A D D I T I O N A L T A B L E S
Table 1. Overview of dressing types
Basic wound contact dressings
Low adherence dressings and wound contact material
Absorbent dressings
Advanced wound dressings
Hydrogel dressings
Films: permeable film and membrane dressings
Soft polymer dressings
Hydrocolloid dressings
Foam dressings
Alginate dressings
Capillary-action dressings
Odour-absorbant dressings
Anti-microbial dressings
Honey
Iodine
Silver
PHMB (polyhexamethylene biguanide or
polihexanide)
Other
Specialist dressings
Protease-modulating matrix
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Table 2. Summary of included reviews
Review ID Cochrane Re-
view?
Number
of databases
searched
Search date Interventions
included
Included
wound types
Other
outcomes re-
ported in the
review
that are rel-
evant to this
overview
Method of
risk of bias/
quality
assess-
ment used in
the review
Dumville
2013d
Y 6 2013 Included any
RCT in which
the pres-
ence or ab-
sence of a hy-
drogel dress-
ing was the
only system-
atic difference
between treat-
ment groups
Foot ulcers in
people of any
age with DM
Health-related
quality of life;
amputa-
tions; adverse
events, includ-
ing pain; cost
Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
Dumville
2013c
Y 6 2013 Included any
RCT in which
the presence
or absence of
a foam dress-
ing was the
only system-
atic difference
between treat-
ment groups
Foot ulcers in
people of any
age with DM
Health-related
quality of life;
amputa-
tions; adverse
events, includ-
ing pain; cost
Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
Dumville
2013b
Y 6 2013 Included any
RCT in which
the presence
or absence
of a hydrocol-
loid dressing
was the only
systematic dif-
ference
between treat-
ment groups
Foot ulcers in
people of any
age with DM
Health-related
quality of life;
amputa-
tions; adverse
events, includ-
ing pain; cost
Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
Dumville
2013a
N 6 2013 Included any
RCT in which
the pres-
ence or ab-
Foot ulcers
in people with
DM
N/A Stan-
dard GRADE
assessment for
direct
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Table 2. Summary of included reviews (Continued)
sence of a algi-
nate dressing
was the only
systematic dif-
ference
between treat-
ment groups
estimates. Es-
timates from
the MTC was
as-
sessed using an
ad hoc modi-
fied version of
GRADE de-
veloped by the
study authors
Dumville
2012
Y 6 2012 Included any
RCT compar-
ing one dress-
ing treatment
with another
Foot ulcers in
people of any
age with DM
Health-related
quality of life;
amputa-
tions; adverse
events, includ-
ing pain; cost
Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
Edwards 2010 Y 6 2011 Included any
RCT compar-
ing hydrogel
dressing with
good wound
care or gauze
Foot ulcers
in people with
DM (neu-
ropathic, neu-
roischaemic or
ischaemic ae-
tiology)
Num-
ber of compli-
cations/
adverse events;
quality of life
Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
Game 2012 N 6 2010 Included any
RCT compar-
ing:
1. basic
wound
contact
dressing with
hydrofibre
dressing or
iodine-
impregnated
dressing;
2. alginate
Foot ulcers
in people with
DM
Amputation Each study
was scored for
method-
ological qual-
ity using scor-
ing lists spe-
cific for
each study de-
sign and based
on check-
lists developed
by the Dutch
Cochrane
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Table 2. Summary of included reviews (Continued)
dressing with
silver-
hydrofibre
dressing
Center (www.
cochrane.nl/
index.html)
Voigt 2012 N 2 2011 Included any
RCT compar-
ing Hyalofill
dressing with
basic wound
contact dress-
ing
Foot ulcers
in people with
DM down to
and including
bone (Wagner
class 4), dia-
betic and neu-
ropathic lower
ex-
tremity ulcers,
venous leg ul-
cers, partial or
full skin thick-
ness burns,
and surgical
removal of the
epithelial layer
of skin
None Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
Storm-
Versloot 2010
Y 6 2009 Included any
RCT compar-
ing silver-hy-
drofi-
bre dressing
with alginate
dressing
Preventing in-
fection or pro-
mot-
ing the heal-
ing, or both,
of uninfected
wounds of any
aetiology. Peo-
ple aged 18
years and over
with any type
of wound
Adverse
events; pain;
health related
quality of life;
length of hos-
pital stay;
costs
Standard
Cochrane
’Risk of bias’
assessment
as outlined in
Cochrane
Handbook for
Systematic
Reviews of In-
terventions (
Higgins 2011)
.
Hinchliffe
2008b
N 4 2006 Included any
RCT compar-
ing:
basic wound
contact dress-
ing with algi-
nate dressing
or hydrofibre
dressing
or foamdress-
ing
Chronic foot
ulcers in peo-
ple aged
18 years or
older with ei-
ther type 1 or
type 2 DM
N/A Each study
was scored for
methodolog-
ical quality us-
ing design-
specific scor-
ing, based on
checklists de-
veloped by the
Dutch
Cochrane
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Table 2. Summary of included reviews (Continued)
Center (www.
cochrane.nl/
index.html)
Nelson 2006 N 16 2002 Included any
RCT compar-
ing hydrogel
dressing with
basic wound
contact dress-
ing
Foot ulcers
in adults with
DM
Num-
ber and dura-
tion of hospi-
tal admissions
for diabetic
foot problems
The method-
ological qual-
ity
of RCTs was
assessed using
the
Jadad (Jadad
1996) criteria
O’Meara
2000
N 19 2000 Included any
RCT compar-
ing:
1. foam
dressing with
matrix-
hydrocolloid
dressing or
alginate
dressing;
2. basic
wound
contact
dressing with
alginate
dressing or
foam
dressing
Chronic
wounds, foot
ulcers in peo-
ple with dia-
betes, pressure
ulcers, chronic
leg
ulcers (caused
by venous, ar-
terial or mixed
insufficiency)
, pilonidal si-
nuses, non-
healing surgi-
cal wounds
and chronic
cavity wounds
N/A Details
of study qual-
ity assessment
were provided
in appendix 6.
However the
risk of bias as-
sessment tool
used in this re-
view was not
reported
explicitly
Mason 1999a N 8 Searched from
1983, but
search
date was not
reported
Included any
RCT compar-
ing:
1. foam
dressing with
matrix-
hydrocolloid
dressing
oralginate
dressing;
2. basic
wound
contact
dressing with
foam
dressing
Foot ulcers
in people with
DM
N/A Methodof risk
of bias/quality
assess-
ment was not
reported ex-
plicitly in this
study
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Table 2. Summary of included reviews (Continued)
oralginate
dressing
Abbreviations
MTC: Mixed Treatment comparison
N: no
N/A: Not applicable
RCT: randomised controlled trial
Y: yes
Table 3. AMSTAR assessment of included Cochrane reviews
AMSTAR crite-
ria
(for all included
Cochrane
reviews)
Storm-Versloot
2010
Edwards 2010 Dumville 2013a Dumville 2013b Dumville 2013c Dumville 2013d
A priori design Y Y Y Y Y Y
Duplicate selec-
tion and extrac-
tion*
Y N Y Y Y Y
Comprehensive
literature search
Y Y Y Y Y Y
Searched for re-
ports regardless
of pub-
lication type or
language
Y Y Y Y Y Y
Excluded/in-
cluded list pro-
vided
Y Y Y Y Y Y
Char-
acteristics of in-
cluded studies
provided
Y Y Y Y Y Y
Quality assess-
ment of
included stud-
ies assessed and
presented
Y Y Y Y Y Y
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Table 3. AMSTAR assessment of included Cochrane reviews (Continued)
Qual-
ity used appro-
priately in for-
mulating
conclusions
Y Y Y Y Y Y
Methods
used to com-
bine studies ap-
propriate
Y Y Y Y Y Y
Publication
bias assessed
Y N/A N/A N/A N/A N/A
Conflict of in-
terest stated
Y Y Y Y Y Y
Total score (out
of a maximum
of 11)
11 9 10 10 10 10
* In the AMSTAR assessment we coded “YES” where checking of study selections and data extraction was reported; we coded “NO”
where only study exclusions were checked.
Abbreviations
N: no
N/A: not applicable
Y: yes
Table 4. AMSTAR assessment of included non-Cochrane reviews
AMSTAR cri-
te-
ria (for all in-
cluded non-
Cochrane re-
views)
O’Meara
2000
Hinchliffe
2008b
Mason 1999a Game 2012 Nelson 2006 Dumville 2012 Voigt 2012
A priori de-
sign
Y Y Y Y Y Y Y
Duplicate se-
lection and
extraction *1
Y Y Y Y Y Y Y
Comprehen-
sive literature
search
Y Y Y Y Y Y Y
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Table 4. AMSTAR assessment of included non-Cochrane reviews (Continued)
Searched for
re-
ports regard-
less of publi-
cation type or
language
Y Y Y Y Y Y Y
Excluded/
included list
provided
Y N N N N N Y
Charac-
teristics of in-
cluded stud-
ies provided
Y Y Y Y Y Y Y
Quality
assessment of
included
studies
assessed and
presented
Y Y Y Y Y Y Y
Quality used
ap-
propriately in
formulating
conclusions
Y Y Y Y Y Y Y
Methods
used to com-
bine studies
appropriate *
2
Y N/A N/A N/A N/A N/A Y
Publication
bias assessed
N/A N/A N/A N/A NA Y Y
Con-
flict of inter-
est stated *3
N N N N N Y N
Total score
(out of amax-
imum of 11)
9 7 7 7 7 9 10
*1. In the AMSTAR assessment we coded “YES” where checking of study selections and data extraction was reported; we coded “NO”
where only study exclusions were checked
39Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
*2. In the AMSTAR assessment we coded the synthesis criterion as not applicable (N/A) for reviews where no meta-analysis was
conducted
*3. For the AMSTAR assessment we coded the funding criterion “NO” if funding for individual studies not reported
Abbreviations
N: no
N/A: not applicable
Y: yes
Table 5. Comparison 1: review data for basic wound contact dressing versus alginate dressing
Comparison 1
Basic wound contact dressing versus alginate dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing performance
Dumville 2013a
Primary
outcomes:
time to ul-
cer healing; pro-
portion of ulcers
healed within
specific time
Cochrane
review
RCTs: 3
Total N = 191
Alginate: n = 109
BWC: n = 82
Ahroni 1993(n =
39)*
Follow-up: min-
imum 4 weeks
Alginate: n = 20
BWC: n = 19
Donaghue 1998
(n = 75)*
Follow-up: 8
weeks
Alginate: n = 50
BWC: n = 25
Lalau 2002 (n =
77)
Follow-up: 6
weeks, unclear if
only 4-week data
analysed
Alginate: n = 39
BWC: n = 38
% ulcers healed
Pooled analysis
(fixed-effect)
from 2 RCTs:
RR 1.09 (95%
CI 0.66 to 1.80)
; I² 27%; Chi² P
value 0.24
Trial data re-
ported
Ahroni 1993
Alginate 5/20
(25%) vs BWC
7/19 (37%); RR
0.68 (95% CI 0.
26 to 1.77)
Donaghue 1998
Alginate
24/50 (48%) vs
9/25 (26%); RR
1.33 (95% CI 0.
73 to 2.42)
Mean time to
healing (weeks)
Trial data re-
ported
Donaghue 1998
Alginate 6.2 (SD
NR Trial data
reported
Amputations
Ahroni 1993
4 (2/group) all after
the 4-week follow-
up
Other AEs
Ahroni 1993
Alginates: 6 (4 an-
tibiotic treatment,
1 death, 1 septi-
caemia) vs BWC: 4
(3 antibiotic treat-
ment, 1 death)
AEs
Donaghue 1998
6 events, not de-
scribed, group allo-
cation unclear
Hospitalisation
Ahroni 1993
Alginate 2; BWC 1
NR NR
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Table 5. Comparison 1: review data for basic wound contact dressing versus alginate dressing (Continued)
0.4) vs BWC 5.8
(SD 0.4)
Dumville 2012
Primary
outcome:
pro-
portion of ulcers
healed within
specific time
Mixed
treatment com-
parison
Non-Cochrane
review
Direct estimate
RCTs: 2
Total N = 114
Alginate: n = 70
BWC: n = 44
Ahroni 1993(n =
39)*
Alginate: n = 20
BWC: n = 19
Donaghue 1998
(n = 75)*
Alginate: n = 50
BWC: n = 25
% ulcers healed
Pooled analyses
(fixed-effect)
from 2 RCTs
Direct estimate
OR 1.26 (95%
CrI 0.55 to 2.46)
MTC estimate
OR 1.29 (95%
CrI 0.57 to 2.51)
NR NR NR NR
Hinchliffe
2008b
Pri-
mary outcome:
proportion of ul-
cers healed
Non-Cochrane
review
RCTs: 2
Total N = 152
Alginate: n = 89
BWC: n = 63
Donaghue 1998
(n = 75)*
Alginate: n = 50
BWC: n = 25
Lalau 2002 (n =
77)
Alginate: n = 39
BWC: n = 38
% ulcers healed
Trial data re-
ported
Donaghue 1998
Alginate: 48% of
n = 50
BWC: 36% of n
= 25
Lalau 2002
NR
NR NR NR NR
O’Meara 2000
Primary
outcome:
% ulcers healed
Non-Cochrane
review
RCTs: 1
Total N = 75
Donaghue 1998
(n = 75)*
Alginate: n = 50
BWC: n = 25
% ulcers healed
Trial data re-
ported
Donaghue 1998
Alginate:24/44,
BWC:9/17
OR 1.07(95%
CI 0.36 to 3.25)
Mean time to
healing
Trial data re-
ported
Donaghue 1998
Alginate: 43.4 ±
19.8 days
BWC: 40.6 ± 21
days
NR Trial data
reported
Donaghue 1998
No difference in
the
number or sever-
ity of reported ad-
verse reactions be-
tween groups
NR Trial data reported
Donaghue 1998 Pa-
tients’ assessment of per-
ceived efficacy
favoured alginate com-
pared to
previous treatment
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Table 5. Comparison 1: review data for basic wound contact dressing versus alginate dressing (Continued)
Mason 1999a
Primary
outcome:
% ulcer healed
Non-Cochrane
review
RCTs: 2
Total N = 114
Alginate: n = 70
BWC: n = 44
Ahroni 1993 (n
= 39)
Alginate: n = 20
BWC: n = 19
Donaghue 1998
(n = 75)*
Alginate: n = 50
BWC: n = 25
% ulcers healed
Trial data re-
ported
Ahroni 1993
Alginate 5/20
(25%) vs BWC
7/19 (37%)
%
wounds healed
eventually (un-
specified time)
Ahroni 1993
Alginate: 12/20
(60%)
BWC: 14/19
(74%)
Donaghue 1998
Alginate: 24/44
(55%), BWC: 9/
17 (53%)
Mean time to
healing
Trial
data reported
Donaghue 1998
Alginate 43.4 ±
19.8 days
BWC: 40.6 ± 21
days
NR Trial data
reported
Withdrawals
Donaghue 1998
Alginate 12% vs
BWC 32%
NR NR
Abbreviations
AE: adverse event
BWC: basic wound contact dressing
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
MTC: mixed treatment comparison
NR: not reported
OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
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Table 6. Comparison 2: review data for basic wound contact dressing versus hydrogel dressing
Comparison 2
Basic wound contact dressing versus hydrogel dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing
performance
Dumville 2013d
Pri-
mary outcome:
number of ulcers
healed
Cochrane
review
RCTs: 3
Total N = 198
Hydrogel: n = 89
BWC: n = 63
D’Hemecourt
1998 (n = 138)*
Follow-up: 20
weeks
Hydrogel: n = 70
BWC: n = 68
Jensen 1998 (n =
31)*
Follow-up: 16
weeks
Hydrogel: n = 14
BWC: n = 17
Vandeputte
1997 (n = 29)*
Follow-up: 12
weeks
Hydrogel: n = 15
BWC: n = 14
Ulcers healed
Pooled anal-
ysis (fixed-effect)
from 3 RCTs:
RR 1.80 (95%
CI 1.27 to 2.56)
; I² 0%; Chi² P
value 0.77
Trial data re-
ported
D’Hemecourt
1998
Hydrogel: 25/70
vs BWC 15/68;
RR 1.62 (95%
CI 0.94 to 2.80)
Jensen 1998
Hydrogel 11/14
vs BWC 6/17;
RR 2.23 (95%
CI 1.11 to 4.48)
Vandeputte
1997
Hydrogel 14/15
vs BWC 7/14;
RR 1.87 (95%
CI 1.09 to 3.21)
NR Trial data
reported
Participants with
AEs
D’Hemecourt
1998
Hydrogel: 19/70
(27%) vs BWC 25/
68 (37%); RR 0.74
(95%CI 0.45 to 1.
21)
Jensen 1998
Hydrogel 3 vs
BWC 4
Amputations
Jensen 1998
Hydrogel 1 vs
BWC 0
Infection-related
complications
Vandeputte 1997
Hydrogel: 1/
15 (7%) vs BWC7/
14 (50%); RR 0.14
(95% CI 0.02 to 1.
01) NB unblinded
assessment*
Trial data
reported
Cost/day (USD)
Jensen 1998
Hydrogel 7.
01 versus BWC 12.
28. Costs not col-
lected/compared as
part of full eco-
nomic evaluation
NR
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
Direct estimate
RCTs: 3
Total N: 198
Hydrogel: n = 89
BWC: n = 63
D’Hemecourt
1998 (n = 138)*
Hydrogel: n = 70
BWC: n = 68
Jensen 1998 (n =
% ulcers healed
Pooled analyses
Direct estimate:
OR 3.10 (95%
CrI 1.51 to 5.50)
MTC estimate:
OR 3.33 (95%
CrI 1.65 to 6.11)
NR NR NR NR
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Table 6. Comparison 2: review data for basic wound contact dressing versus hydrogel dressing (Continued)
31)*
Hydrogel: n = 14
BWC: n = 17
Vandeputte
1997 (n = 29)*
Hydrogel: n = 15
BWC: n = 14
Edwards 2010
Primary
outcome: num-
ber of wounds
healed
Cochrane
review
RCTs: 3
Total N: 198
Hydrogel: n = 89
BWC: n = 63
D’Hemecourt
1998 (n = 138)*
Hydrogel: n = 70
BWC: n = 68
Jensen 1998 (n =
31)*
Hydrogel: n = 14
BWC: n = 17
Vandeputte
1997 (n = 29)*
Hydrogel: n = 15
BWC: n = 14
% ulcers healed
Pooled anal-
ysis (fixed-effect)
from 3 RCTs:
RR 1.84 (95%
CI 1.30 to 2.61)
Trial data re-
ported
D’Hemecourt
1998 Hydrogel:
25/70 vs BWC
15/68
Jensen 1998
Hydrogel 12/14
(85%) vs BWC
8/17 (46%)**
Vandeputte
1997
Hydrogel 14/15
vs BWC 7/14
Pooled estimate of
complications/AE
from all 3 trials
Hydrogel 22 events
vs BWC 36 events.
Fixed-effect RR 0.
60 (95%CI 0.38 to
0.95); random-ef-
fects RR 0.56 (95%
CI 0.25 to 1.25). I²
31%
Trial data
reported
Infections
D’Hemecourt
1998
Hydrogel
19/70 (27%) vs 25/
68 (37%) RR 0.74
(95%CI 0.45 to 1.
21)*
Infection-related
complications
Vandeputte 1997
Hydrogel:
1/15 (7%) vs BWC
7/14 (50%); RR 0.
13 (95%CI 0.02 to
0.95)**
Complications
Jensen 1998
Hydro-
gel 2/14(14%) vs
BWC 4/17 (24%);
RR 0.61 (95% CI
0.13 to 2.84). In-
cluded events: am-
putation, increased
eschar formation,
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Table 6. Comparison 2: review data for basic wound contact dressing versus hydrogel dressing (Continued)
cellulitis, worsened
with increased es-
char formation
Pain
D’Hemecourt
1998
Hydrogel: 11/
70 (16%) vs BWC
10/68 (15%); RR
0.74 (95% CI 0.
45 to 1.21 favour-
ing BWC) unclear
how pain reported
Hinchliffe
2008b
Primary
outcome: num-
ber of wounds
healed
Non-Cochrane
review
Jensen 1998 (n =
31)
Hydrogel: n = 14
BWC: n = 17
% wounds
healed
Trial data re-
ported
Jensen 1998
Hydrogel 12/14
(85%) vs BWC
8/17 (46%)
NR NR NR NR
Nelson 2006
Primary
outcome: num-
ber of wounds
healed
Non-Cochrane
review
Vandeputte
1997 (n = 29)*
Hydrogel: n = 15
BWC: n = 14
% wounds
healed
Trial data re-
ported
Vandeputte
1997
Hydrogel 14/15
(93%) vs BWC
5/14 (36%); RR
2.61 (95% CI 1.
45 to 5.76)
Trial data
reported
Vandeputte 1997
Amputation
required
Hydrogel
1/15 (7%) vs BWC
5/14 (36%); RR 5.
4 (95% CI 0.98 to
32.7)
Infection
Hydrogel 1/15
(7%) vs BWC 7/14
(7%); RR 7.5 (95%
CI 1.47 to 44.1)
Antibiotics
needed
Hydrogel 1/15
(7%) vs BWC 14/
14 (100%); RR 0.
067 (95% CI 0.01
to 0.31)
*What Dumville defined as AE was all covered by infections in Edwards. Edwards noted that it was unclear how infection had been
defined
**Events from the Jensen trial reported in Edwards differed from those reported in Dumville; so RR differs slightly. Checking the trial
report showed that Dumville data seem accurate
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Abbreviations
AE: adverse event
BWC: basic wound contact dressing
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
MTC: mixed treatment comparison
NR: not reported
OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
USD: USA dollars
Table 7. Comparison 3: review data for basic wound contact dressing versus hydrofibre dressing
Comparison 3
Basic wound contact dressing versus hydrofibre dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing
performance
Dumville 2013b
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Cochrane
review
RCTs: 2
Total N: 229
Hydrofibre: n =
113
BWC: n = 116
Jeffcoate 2009 (n
= 209)*
Follow-up: 24
weeks
Hydrofibre: n =
103
BWC: n = 106
Piaggesi 2001 (n
= 20)*
Follow-up: NR;
maximum time
reported approx-
imately 350 days
Hydrofibre: n =
10
BWC: n = 10
% ulcers healed
Pooled analysis
(random-
effects) from 2
RCTs: RR 1.01
(95% CI 0.74 to
1.38); I² 54%;
Chi² P value 0.
14
Trial data re-
ported
Jeffcoate 2009
Hydrofibre 46/
103 (45%)
vs BWC 41/106
(39%); RR 1.15
(95% CI 0.84 to
1.59)
Piaggesi 2001
Hydrofibre 9/10
(90%) vs BWC
10/10 (100%);
RR 0.90 (95%
Trial data re-
ported
Jeffcoate 2009
No difference in
disease-specific
or generic QoL
Trial data re-
ported
Amputations
Jeffcoate 2009
Hydrofibre 4 vs
BWC 2
Piaggesi 2001
Hydrofibre 5 vs
BWC 3
Serious AEs
Jeffcoate 2009
Hydrofibre 28 vs
BWC 35
Non-serious
AEs
Jeffcoate 2009
Hydrofibre 227
vs BWC 244
AEs reported
Piaggesi 2001
Hydrofibre 2 vs
BWC 5
Trial data re-
ported
Cost per healed
ulcer (GBP)
Jeffcoate 2009
Hyrofibre 836 vs
BWC 362
Days be-
tween dressing
changes (mean)
Piaggesi 2001
Hydrofibre 21 vs
BWC 2.4
NR
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Table 7. Comparison 3: review data for basic wound contact dressing versus hydrofibre dressing (Continued)
CI 0.69 to 1.18)
Mean time to
healing (days)
Trial data re-
ported
Jeffcoate 2009
Hydrofibre 125.
8 (SD 55.5) vs
BWC 130.7 (SD
52.4)
Piaggesi 2001
Hydrofibre 127
(SD 46) vs BWC
234 (SD 61)
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
Direct estimate
RCTs: 2
Total N: 229
Hydrofibre: n =
113
BWC: n = 116
Jeffcoate 2009
(n= 209)*
Hydrofibre: n =
103
BWC: n = 106
Piaggesi 2001 (n
= 20)*
Hydrofibre: n =
10
BWC: n = 10
% ulcers healed
Pooled analyses
Direct estimate:
OR 1.28 (95%
CrI 0.71 to 2.14)
MTC estimate:
OR 1.28 (95%
CrI 0.72 to 2.13)
NR NR NR NR
Game 2012
Primary
outcome: num-
ber of wounds
healed
Non-Cochrane
review
RCTs: 1
Total N: 209
Hydrofibre: n =
103
BWC: n = 106
Jeffcoate 2009 (n
= 209)*
Hydrofibre: n =
103
BWC: n = 106
% ulcers healed
Trial data re-
ported
Jeffcoate 2009
Hydrofibre 44.
7% vs BWC 38.
7%
Mean time to
heal (days)
Trial data re-
ported
Jeffcoate 2009
Hydrofibre: 72.
4 (SD 20.6) vs
BWC 75.1 (SD
18.1)
NR Trial data re-
ported
Secondary
infection
Jeffcoate 2009
Hydrofibre 54 vs
BWC 48. Three-
way compari-
son reported as P
value < 0.001
Trial data re-
ported
Mean dressing
cost per patient
(GBP)
Jeffcoate 2009
Hydrofibre 43.
60 vs
BWC 14.85.
Three-way com-
parison reported
as P value < 0.05
NR
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Table 7. Comparison 3: review data for basic wound contact dressing versus hydrofibre dressing (Continued)
Hinchliffe
2008b
Primary
outcome: num-
ber of wounds
healed
Non-Cochrane
review
RCTs: 1
Total N: 20
Hydrofibre: n =
10
BWC: n = 10
Piaggesi 2001 (n
= 20)
Hydrofibre: n =
10
BWC: n = 10
Time to heal
(days)
Trial data re-
ported
Piaggesi 2001
Hydrofibre: 127
(SD 46) vs BWC
234 (SD 25?)
NR NR NR NR
Abbreviations
AE: adverse event
BWC: basic wound contact dressing
CI: confidence interval
CrI: credible interval
GBP: British pounds (Sterling)
HRQoL: health-related quality of life
MTC: mixed treatment comparison
NR: not reported
OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
SD: standard deviation
Table 8. Comparison 4: review data for basic wound contact dressing versus Hyalofill dressing
Comparison 4
Basic wound contact dressing versus Hyalofill dressing
Review Included trials Wound healing HRQoL Adverse events Resource use Dressing performance
Voigt 2012
Pri-
mary outcome:
number of ulcers
healed
Non-Cochrane
review
RCTs: 1
Total N: 30
Hyalofill: n = 15
BWC: n = 15
Edmonds 2000
(n = 30)
Follow-up: 12
weeks
Hyalofill: n = 15
BWC: n = 15
% ulcers healed
Trial data re-
ported
Edmonds 2000
Hyalofill 10/15
(67%) vs BWC
3/15 (20%)
P value < 0.05
NR NR NR NR
Abbreviations
BWC: basic wound contact dressing
HRQoL: health-related quality of life
NR: not reported
RCT: randomised controlled trial
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Table 9. Comparison 5: review data for basic wound contact dressing versus iodine-impregnated dressing
Comparison 5
Basic wound contact dressing versus iodine-impregnated dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing
performance
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
Direct estimate
RCTs: 1
Total N: 214
Iodine: n = 108
BWC: n = 106
Jeffcoate 2009 (n
= 214)*
Follow-up: 24
weeks
Iodine: n = 108
BWC: n = 106
% ulcers healed
Pooled analyses
Direct estimate:
OR 1.27 (95%
CI 0.74 to 2.19)
MTC estimate:
OR 1.28 (95%
CrI 0.71 to 2.12)
NR NR NR NR
Game 2012
Primary
outcome: num-
ber of wounds
healed by 24
weeks
Non-Cochrane
review
RCTs: 1
Total N: 214
Iodine: n = 108
BWC: n = 106
Jeffcoate 2009 (n
= 214)*
Iodine: n = 108
BWC: n = 106
% ulcers healed
Trial data re-
ported
Jeffcoate 2009
Iodine 44.4% vs
BWC 38.7%
Mean time to
healing
Jeffcoate 2009
Iodine 74.1 (SD
20.6)
days vs BWC 75.
1 (SD 18.1) days
NR Trial data
reported
Secondary infec-
tion
Jeffcoate 2009
Iodine 71 vs BWC
48
Three-way com-
parison reported as
P value < 0.001
Trial data
reported
mean
dressing cost per
patient (GBP)
Jeffcoate 2009
Iodine 17.
48 vs BWC 14.85.
Three-way com-
parison reported as
P value < 0.05
NR
Abbreviations
BWC: basic wound contact dressing
CI: confidence interval
CrI: credible interval
GBP: British pounds (Sterling)
HRQoL: health-related quality of life
MTC: mixed treatment comparison
NR: not reported
OR: odds ratio
SD: standard deviaiton
RCT: randomised controlled trial
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Table 10. Comparison 6: review data for basic wound contact dressing versus foam dressing
Comparison 6
Basic wound contact dressing versus foam dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing performance
Dumville 2013c
Pri-
mary outcome:
number of ulcers
healed
Cochrane
review
RCTs: 3
Total N: 67
Foam: n = 36
BWC: n = 31
Blackman 1994
(n = 18)*
Follow-up:
6 months but 2
months reported
here due to cross-
over
Foam: n = 11
BWC: n = 7
Mazzone 1993
(n = 19)*
Follow-up: 8
weeks
Foam: n = 11
BWC: n = 8
Roberts 2001 (n
= 30)*
Follow-up: 13
weeks
Foam: n = 14
BWC: n = 16
% ulcers healed
Pooled analysis
(fixed-effect)
from 2 RCTs:
RR: 2.03 (95%
CI 0.91 to 4.55)
; I² 0%; Chi² P
value 0.64
Trial reported
data
Blackman 1994
Foam 3/11
(27%) vs BWC
0/7 (0%); RR 4.
67 (95%CI 0.28
to 78.68)
Mazzone 1993
Foam 7/11
(64%) vs BWC
2/8 (25%); RR
2.55 (95% CI 0.
71 to 9.16)
Roberts 2001
Foam 6/14
(43%) vs BWC
4/16 (25%); RR
1.71, (95%CI 0.
60 to 4.86)
NR None of the 3
included trials re-
ported any data for
any secondary out-
come evaluated
NR NR
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
Direct estimate
RCTs: 3
Total N: 67
Foam: 36
BWC: 31
Blackman 1994
(n = 18)*
Foam: n = 11
BWC: n = 7
% ulcers healed
Pooled analyses
Direct estimate:
OR 4.10 (95%
CrI 1.07 to 10.
07)
MTC estimate:
OR 4.32 (95%
NR NR NR NR
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Table 10. Comparison 6: review data for basic wound contact dressing versus foam dressing (Continued)
Mazzone 1993
(n = 19)*
Foam:n = 11
BWC: n = 8
Roberts 2001 (n
= 30)* Foam: n =
14
BWC: n = 16
CrI 1.56 to 9.85)
Hinchliffe
2008b
Primary
outcome: num-
ber of wounds
healed
Non-Cochrane
review
Blackman 1994
(n = 18)
Foam: n = 11
BWC: n = 7
% ulcers healed
by 2 months
Trial reported
data
Blackman 1994
Foam 3/11 vs
BWC 0/7
NR NR NR NR
O’Meara 2000
Primary
outcome:
% ulcers healed
Non-Cochrane
review
Blackman 1994
(n = 18)
Foam: n = 11
BWC: n = 7
% ulcers healed
by 2 months
Trial reported
data
Blackman 1994
Foam 3/11 vs
BWC0/7; OR6.
39 (95%CI 0.54
to 75.62)
Also reported:
change in ulcer
area (reduction)
Foam 35 ± 16%
vs BWC 105 ±
26%; OR -70.00
(95% CI 2.01 to
99.78)
NR NR NR NR
Mason 1999a
Primary
outcome:
% ulcers healed
Non-Cochrane
review
Blackman 1994
(n = 18)
Foam: n = 11
BWC: n = 7
% ulcers healed
by 2 months
Trial reported
data
Blackman 1994
Foam 3/11 vs
BWC 0/7
Also reported:
change in ulcer
area (reduction)
Foam 35 ± 16%
vs BWC 105 ±
26%;P value <0.
03
NR NR NR NR
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Abbreviations
BWC: basic wound contact dressing
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
NR: not reported
MTC: mixed treatment comparison
OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
Table 11. Comparison 7: review data for basic wound contact dressing versus protease-modulating matrix dressing
Comparison 7
Basic wound contact dressing versus protease-modulating matrix dressing
Review Included trials Wound healing HRQoL Adverse events Resource use Dressing performance
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
Direct estimate
RCTs: 1
Total N: 276
Protease-matrix:
n = 138
BWC: n = 138
Veves 2002(n =
276)
Follow-up: 12
weeks
Protease-matrix:
n = 138
BWC: n = 138
% ulcers healed
Pooled analyses
Direct estimate:
OR 1.49 (95%
CI 0.90 to 2.47)
MTC estimate:
OR 1.54 (95%
CrI 0.89 to 2.47)
NR NR NR NR
Abbreviations
BWC: basic wound contact dressing
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
NR: not reported
MTC: mixed treatment comparison
OR: odds ratio
RCT: randomised controlled trial
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Table 12. Comparison 8: review data for foam dressing versus alginate dressing
Comparison 8
Foam dressing versus alginate dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing performance
Dumville 2013a
Primary
outcomes: time
to ulcer healing;
ulcers healed
within specific
time
Cochrane
review
RCTs: 2
Total N: 50
Foam: n = 25
Alginate: n = 25
Foster 1994(n =
30)*
Follow-up: 8
weeks
Foam: n = 15
Alginate: n = 15
Baker 1993(un-
published; n =
20)
Follow-up: 12
weeks
Foam: n = 10
Alginate: n = 10
% ulcers healed
Pooled analyses
(fixed-
effect) based on
2 RCTs: RR 0.
67 (95%CI 0.41
to 1.08); I² 45%;
Chi² P value 0.
18
Trial reported
data
Foster 1994
Alginate 8/15
(53%) vs foam9/
15 (60%); RR 0.
89 (95%CI 0.47
to 1.67)
Baker 1993
Alginate 4/10
(40%) vs foam9/
10 (90%); RR 0.
44 (95%CI 0.20
to 0.98)
Median time to
healing
Trial reported
data
Foster 1994
Alginate
42 vs foam 40
(estimated from
graph)
Baker 1993
Alginate
not reached by
84 days vs foam:
28 days
NR Trial reported
data
AEs
Foster 1994
Foam 0 vs alginate
4 (severe pain: 1;
plugging of plan-
tar lesion blocking
drainage: 3 (1 cel-
lulitis)
NR NR
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Table 12. Comparison 8: review data for foam dressing versus alginate dressing (Continued)
Dumville 2013c
Primary
outcomes: time
to ulcer healing;
ulcers healed
within specific
time
Cochrane
review
RCTs: 2
Total N: 50
Foam: n = 25
Alginate: n = 25
Foster 1994(n =
30)*
Foam: n = 15
Alginate: n = 15
Baker 1993(un-
published; n =
20)
Foam: n = 10
Alginate: n = 10
% ulcers healed
Pooled analysis
(fixed-
effect) based on
2 RCTs: RR 1.
50 (95%CI 0.92
to 2.44); I² 45%;
Chi² P value 0.
18
Trial reported
data
Foster 1994
Alginate 8/15
(53%) vs foam9/
15 (60%); RR 1.
13 (95%CI 0.60
to 2.11)
Baker 1993
Alginate 4/10
(40%) vs foam
9/10; RR 2.25
(95% CI 1.02 to
4.94)
NR As Dumville 2013a
above
NR NR
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
Direct estimate
RCTs: 2
Total N: 50
Foam: n = 25
Alginate:n = 25
Foster 1994(n =
30)*
Foam: n = 15
Alginate: n = 15
Baker 1993(un-
published; n =
20)
Foam: n = 10
Alginate: n = 10
% ulcers healed
Pooled analyses
Direct estimate:
OR 2.94 (95%
CrI 0.71 to 8.33)
MTC estimate:
OR 3.61 (95%
CrI 1.30 to 8.30)
NR NR NR NR
O’Meara 2000
Primary
outcome:
% ulcers healed
Non-Cochrane
review
RCTs: 2
Total N: 50 (49
reported)
Foam: n = 25
Alginate: n = 25
Foster 1994(n =
30)*
Foam: n = 15
Alginate: n = 15
Baker 1993(un-
% ulcers healed
Pooled analysis
(fixed-ef-
fect) based on 2
RCTs. Foam 18/
25 vs
alginate 12/24;
OR 2.44 (95%
CI 0.78 to 7.57)
Trial reported
data
AEs
Baker 1993
No AE reported
from either group
Foster 1994
As
forDumville 2013a
Trial reported data
Baker 1993
Foam dressing:
1. more absorbent
(P value < 0.001)
2. less adherent (P
value < 0.006)
3. easier to remove
(P value < 0.011) vs
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Table 12. Comparison 8: review data for foam dressing versus alginate dressing (Continued)
published; n =
20, 19 reported?
)
Foam: n = 10
Alginate: n = 10
above; all AEs re-
ported as leading to
withdrawal
alginate
Patient comfort
Good; no significant dif-
ference between groups
Mason 1999a
Primary
outcome:
% ulcers healed
Non-Cochrane
review
RCTs: 1
Total N: 30
Foam: n = 15
Alginate: n = 15
Foster 1994 (n =
30)
Foam: n = 15
Alginate: n = 15
% ulcers healed
Trial reported
data
Foster 1994
Foam 9/15 vs al-
ginate 8/15; OR
1.30 (95% CI 0.
31 to 5.38)
NR NR NR NR
Abbreviations
AE: adverse event
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
MTC: mixed treatment comparison
NR: not reported
OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
Table 13. Comparison 9: review data for foam dressing versus hydrocolloid dressing
Comparison 9
Foam dressing versus hydrocolloid dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing
performance
Dumville 2013b
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Cochrane
review
RCTs: 1
Total N: 40
Foam: n = 20
Hydrocolloid: n
= 20
Clever 1995 (n =
40)*
Follow-up: 12
weeks
% ulcers healed
Trial reported
data
Clever 1995
Foam 14/
20 (70%) vs hy-
drocolloid 16/20
(80%); RR 0.88
(95% CI 0.61 to
NR Trial reported
data
AEs
Clever 1995
Foam 5 vs hydro-
colloid 1
Trial reported
data
Mean
number of dress-
ing changes be-
tween clinical vis-
its
Clever 1995
NR
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Table 13. Comparison 9: review data for foam dressing versus hydrocolloid dressing (Continued)
Foam: n = 20
Hydrocolloid: n
= 20
1.26)
Median time to
healing (days)
Trial reported
data
Clever 1995
Foam 16.5
(range 4 to 52) vs
hydrocolloid 15.
5 (range 4 to 76
days)
Foam 2.37 vs hy-
drocolloid 2.23
Dumville 2013c
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Cochrane
review
RCTs: 1
Total N: 40
Foam: n = 20
Hydrocolloid: n
= 20
Clever 1995 (n =
40)*
Foam: n = 20
Hydrocolloid: n
= 20
% ulcers healed
Trial reported
data
Clever 1995
Hydrocolloid
16/20 (80%) vs
foam 14/20
(70%); RR 1.14
(95% CI 0.80 to
1.64)
NR As for Dumville
2013b above
As for Dumville
2013b above
NR
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
RCTs: 1
Total N: 40
Foam: n = 20
Hydrocolloid: n
= 20
Clever 1995 (n =
40)*
Foam: n = 20
Hydrocolloid: n
= 20
Ulcers healed
Direct estimate:
OR 1.71 (95%
CI 0.40 to 7.34)
MTC estimate:
OR 2.40 (95%
CrI 0.40 to 8.40)
NR NR NR NR
O’Meara 2000
Primary
outcome:
% ulcers healed
Non-Cochrane
review
RCTs: 1
Total N: 40
Foam: n = 20
Hydrocolloid: n
= 20
Clever 1995 (n =
40)*
Foam: n = 20
Hydrocolloid: n
= 20
Time to healing
(days):
Trial reported
data
Clever 1995
Hydrocolloid
25.19 (SD 23.
52) vs foam 20.
43 (SD 14.74);
OR 4.76 (95%
CI -7.41 to 16.
93)
NR Trial reported
data
Withdrawals
Clever 1995
Foam 4 vs hydro-
colloid 2
NR No differences
in patient comfort
based on subjective
product evaluation
(investigator);
showering found
slightly easier
with hydrocolloid
Mason 1999a
Primary
outcome:
RCTs: 1
Total N: 40
Time to healing
(days):
NR NR No differ-
ences in frequency
NR
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Table 13. Comparison 9: review data for foam dressing versus hydrocolloid dressing (Continued)
% ulcers healed
Non-Cochrane
review
Foam: n = 20
Hydrocolloid: n
= 20
Clever 1995 (n =
40)*
Foam: n = 20
Hydrocolloid: n
= 20
Trial reported
data
Clever 1995
Hydrocolloid
25.19 (SD 23.
52) vs foam 20.
43 (SD 14.74)
Also reported
reduction in di-
abetic foot ulcer
area (mm²) at 4
weeks
Hydrocolloid
32.37 (SD 54.
12) vs foam 33.
46 (SD 75.22)
of change of dress-
ing
Abbreviations
AE: adverse event
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
NR: not reported
MTC: mixed treatment comparison
OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
SD: standard deviation
Table 14. Comparison 10: review data for iodine-impregnated dressing versus hydrofibre dressing
Comparison 10
Iodine-impregnated dressing versus hydrofibre dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing
performance
Dumville 2013b
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
RCTs: 1
Total N: 211
Iodine: n = 108
Hydrofibre: n =
103
Jeffcoate 2009 (n
% ulcers healed
Trial data re-
ported
Jeffcoate 2009
Iodine 48/108
(44%) vs 46/103
Disease-spe-
cific or generic
HRQoL
Trial data re-
ported
Jeffcoate 2009
Trial data re-
ported
Jeffcoate 2009
Amputations
Iodine: 1 vs hy-
drofibre 4
Trial data re-
ported
Jeffcoate 2009
Cost per addi-
tional ul-
cer healed (GBP)
NR
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Table 14. Comparison 10: review data for iodine-impregnated dressing versus hydrofibre dressing (Continued)
specific time
Cochrane
review
= 211)**
Follow-up: 24
weeks
Iodine: n = 108
Hydrofibre: n =
103
(45%); RR 1.00
(95% CI 0.74 to
1.34)
Mean time to
healing (days)
Trial data re-
ported
Jeffcoate 2009
Iodine 127.
8 (SD 54.2) vs
hydrofibre 125.8
(SD 55.9)
No difference in
disease-spe-
cific or generic
HRQoL
Serious AEs
Iodine 37 versus
hydrofibre 28
Non-serious
AEs
Iodine 239 vs hy-
drofibre 227
for iodine group:
848
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
RCTs: 1
Total N: 211
Iodine: n = 108
Hydrofibre: n =
103
Jeffcoate 2009 (n
= 211)**
Iodine: n = 108
Hydrofibre: n =
103
% ulcers healed
Pooled analyses
Direct estimate:
OR 0.99 (95%
CI 0.58 to 1.71)
MTC estimate:
OR 1.05 (95%
CrI 0.59 to 1.75)
NR NR NR NR
Game 2012
Primary
outcome: num-
ber of wounds
healed by 24
weeks
Non-Cochrane
review
RCTs: 1
Total N: 211
Iodine: n = 108
Hydrofibre: n =
103
Jeffcoate 2009 (n
= 211)**
Iodine: n = 108
Hydrofibre: n =
103
% ulcers healed
Trial data re-
ported
Jeffcoate 2009
Iodine 44.4%
vs hydrofibre 44.
7%
Time to healing
(days)
Trial data re-
ported
Jeffcoate 2009
Iodine 74.1 (SD
20.6) vs hydrofi-
bre 72.4 (SD 20.
6)
NR Trial data re-
ported
Jeffcoate 2009
Secondary
infection
Iodine 71
vs hydrofibre 51.
Three-way com-
parison reported
as P value < 0.
001
Trial data re-
ported
Mean dressing
cost per patient
(GBP)
Jeffcoate 2009
Io-
dine 17.48 vs hy-
drofibre 43.60.
Three-way com-
parison reported
as P value < 0.05
NR
**This comparison appears to be Missing from the Revman table - only included under other comparisons assessed in Jeffcoate 2009
Abbreviations
AE: adverse event
CI: confidence interval
CrI: credible interval
GBP: British pounds (Sterling)
HRQoL: health-related quality of life
NR: not reported
MTC: mixed treatment comparison
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OR: odds ratio
RCT: randomised controlled trial
RR: risk ratio
SD: standard deviation
Table 15. Comparison 11: review data for alginate dressing versus silver-hydrofibre dressing
Comparison 11
Alginate dressing versus silver-hydrofibre dressing
Review Included trials
(trials that re-
ported
secondary out-
come data are
marked with an
asterisk*)
Wound healing HRQoL Adverse events Resource use Dressing
performance
Dumville 2013a
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Cochrane
review
RCTs: 1
Total N: 134
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
Jude 2007(n =
134)*
Follow-up: 8
weeks
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
% ulcers healed
Trial data re-
ported
Jude 2007
Silver-hydrofi-
bre 21/67 (31%)
vs alginate 15/67
(21%); RR 1.40
(95% CI 0.79 to
2.47)
Time to healing
(days)
Trial data re-
ported
Jude 2007 Silver-
hydrofibre 52.6
(SD 1.8) vs algi-
nate 57.7 (SD 1.
7)
NR Trial data
reported
Jude 2007
AEs
Alginate 26 includ-
ing 1 death
vs silver-hydrofibre
25 events including
1 death
Infections (type
unclear)
Alginate 8 vs hy-
drofibre 14
Discontinuation
due to AE
Alginate 13 vs sil-
ver-hydrofibre 8
Trial data
reported
Number of dress-
ing changes
(mean)
Jude 2007
Alginate 20.8 vs sil-
ver-hydrofibre 21.
9. No measure of
variance reported
NR
Dumville 2012
Primary
outcomes:
time to ulcer
healing; ulcers
healed within
specific time
Non-Cochrane
review
RCTs: 1
Total N: 134
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
Jude 2007(n =
134)*
Follow-up: 8
weeks
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
% ulcers healed
Pooled analyses
Direct estimate:
OR 1.58 (95%
CI 0.73 to 3.43)
MTC estimate:
OR 1.73 (95%
CrI 0.73 to 3.53)
NR NR NR NR
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Table 15. Comparison 11: review data for alginate dressing versus silver-hydrofibre dressing (Continued)
Game 2012
Primary
outcome:
% ulcers healing
Non-Cochrane
review
RCTs: 1
Total N: 134
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
Jude 2007(n =
134)*
Follow-up: 8
weeks
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
% ulcers healed
Trial data re-
ported
Jude 2007
Alginate 22% vs
silver-hydrofibre
31%
Time to heal-
ing (days) Trial
data reported
Jude 2007
Alginate
57.7 (SD 1.7)
vs silver-hydrofi-
bre 52.6 (SD 1.
8)
NR NR NR NR
Storm-Versloot
2010
Primary
outcome:
wound infection
rate and wound
healing
Cochrane
review
RCTs: 1
Total N: 134
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
Jude 2007(n =
134)*
Follow-up: 8
weeks
Alginate: n = 67
Silver-hydrofi-
bre: n = 67
% ulcers healed
Trial data re-
ported
Jude 2007Silver-
hydrofibre 21/67
vs alginate 15/67
(RD 0.09; 95%
CI -0.06 to 0.24)
Time to heal-
ing (days) Trial
data reported
Jude 2007 Silver-
hydrofibre 52.6
(SD 1.8) vs algi-
nate 57.7 (SD 1.
7)
NR Trial data
reported
Jude 2007
Participants de-
veloping infection
Alginate 8/67 vs
hydrofibre 11/67**
RD 0.04 (95% CI -
0.07 to 0.16)
Participants with
AEs (not clearly
defined)
Alginate 26/67
vs hydrofibre 25/67
RD -0.01 (95% CI
-0.18 to 0.15)
NR NR
**Note discrepancy between Dumville and Storm-Versloot on number of infections in hydrofibre dressing - unit of analysis (infections
versus participants) - not clear
Abbreviations
AE: adverse event
CI: confidence interval
CrI: credible interval
HRQoL: health-related quality of life
NR: not reported
MTC: mixed treatment comparison
OR: odds ratio
RCT: randomised controlled trial
RD: risk difference
RR: risk ratio
SD: standard deviation
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A P P E N D I C E S
Appendix 1. Glossary
Word Definition/explanation
Alginate Substance derived from algic acid, derived from seaweed, used in making dressings for wounds
Debridement The removal of foreign material and dead or damaged tissue from a wound
Diabetes mellitus A metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. The two
most common forms are type 1 and type 2; other less common forms also exist
Dressing* A therapeutic or protective material applied to a wound
Gangrene* Death and decay of body tissue, often occurring in a limb, caused by insufficient blood supply and
usually following injury or disease
Hydrocolloid Dressing that reacts with wound exudate to maintain the moisture at the surface of a wound
Hydrogel Water based jelly-like substance, which can be used for the same purpose as hydrocolloid dressings
Insulin Hormone secreted by the pancreas in response to blood glucose levels. It is involved in regulating
blood glucose levels and promotes fuel storage within the body
Ischaemic Deficient blood supply to any part of the body
Ischaemic ulcer Area of skin loss (see ulcer, arterial ulcer) resulting from deficient blood supply
Neuropathy* A disease or abnormality of the nervous system
Occlusive dressing* A dressing that prevents air from reaching a wound or lesion and that retains moisture, heat, body
fluids, and medication
Osteitis* Inflammation of bone
Osteomyelitis Inflammation in the marrow of a bone, can occur as a complication of infected diabetic foot ulcers
Peripheral Outlying, for example: peripheral neuropathy affects the nerves in the outlying parts of the body;
and peripheral vascular disease is disease of the small blood vessels close to the surface of the skin
Ulcer in people with diabetes An area of skin loss resulting from poor blood supply and/or reduced nerve function in the lower
limb caused by diabetes mellitus
Definitions taken from Cochrane Wounds Group Glossary unless marked * when taken from The Free Medical Dictionary (http://
medical-dictionary.thefreedictionary.com).
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Appendix 2. Search strategy to identify non-Cochrane systematic reviews in Ovid MEDLINE
1 exp Occlusive Dressings/ (3359)
2 exp Bandages, Hydrocolloid/ (563)
3 exp Biological Dressings/ (1122)
4 exp Alginates/ (6361)
5 exp Hydrogels/ (8384)
6 exp Silver/ (12518)
7 exp Silver Sulfadiazine/ (737)
8 exp Honey/ (2047)
9 (dressing* or hydrocolloid* or alginate* or hydrogel* or foam or bead or film* or tulle or gauze or non-adherent or non adherent or
silver or honey or matrix).tw. (340728)
10 or/1-9 (349782)
11 exp Foot Ulcer/ (6231)
12 exp Diabetic Foot/ (5195)
13 (diabet* adj3 ulcer*).tw. (2360)
14 (diabet* adj3 (foot or feet)).tw. (4521)
15 (diabet* adj3 wound*).tw. (1194)
16 (diabet* adj3 amputat*).tw. (599)
17 or/11-16 (8927)
18 10 and 17 (657)
19 systematic* review*.tw. (36034)
20 meta-analysis as topic/ (12359)
21 (meta-analytic* or meta-analysis or metanalysis or metaanalysis or meta analysis or meta-synthesis or metasynthesis or meta synthesis
or meta-regression or metaregression or meta regression).tw. (37831)
22 (synthes* adj3 literature).tw. (1042)
23 (synthes* adj3 evidence).tw. (2912)
24 (integrative review or data synthesis).tw. (6729)
25 (research synthesis or narrative synthesis).tw. (437)
26 (systematic study or systematic studies).tw. (5597)
27 (systematic comparison* or systematic overview*).tw. (1409)
28 ((evidence based or comprehensive or critical or quantitative or structured) adj review).tw. (15809)
29 (realist adj (review or synthesis)).tw. (33)
30 or/19-29 (100139)
31 review.pt. (1734481)
32 (medline or pubmed or embase or cinahl or psyc?lit or psyc?info).ab. (58238)
33 ((literature or database* or bibliographic or electronic or computeri?ed or internet) adj3 search*).tw. (39600)
34 (electronic adj3 database*).tw. (6818)
35 included studies.ab. (4054)
36 (inclusion adj3 studies).ab. (4224)
37 ((inclusion or selection or predefined or predetermined) adj criteria).ab. (39033)
38 (assess* adj3 (quality or validity)).ab. (31366)
39 (select* adj3 (study or studies)).ab. (29761)
40 (data adj3 extract*).ab. (21026)
41 extracted data.ab. (4781)
42 (data adj3 abstraction).ab. (615)
43 published intervention*.ab. (83)
44 ((study or studies) adj2 evaluat*).ab. (83681)
45 (intervention* adj2 evaluat*).ab. (4705)
46 (confidence interval* or heterogeneity or pooled or pooling or odds ratio*).ab. (319533)
47 (Jadad or coding).ab. (101847)
48 or/32-47 (631785)
49 31 and 48 (93486)
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50 review.ti. (209748)
51 48 and 50 (30178)
52 (review* adj4 (papers or trials or studies or evidence or intervention* or evaluation*)).tw. (78981)
53 30 or 49 or 51 or 52 (213228)
54 letter.pt. (758034)
55 editorial.pt. (307072)
56 comment.pt. (484716)
57 or/54-56 (1152182)
58 53 not 57 (207741)
59 exp animals/ not humans/ (3749650)
60 58 not 59 (199437)
61 18 and 60 (42)
Appendix 3. Search strategy to identify reports of mixed treatment comparisons in Ovid MEDLINE
1 exp Occlusive Dressings/ (3359)
2 exp Bandages, Hydrocolloid/ (563)
3 exp Biological Dressings/ (1122)
4 exp Alginates/ (6361)
5 exp Hydrogels/ (8384)
6 exp Silver/ (12518)
7 exp Silver Sulfadiazine/ (737)
8 exp Honey/ (2047)
9 (dressing* or hydrocolloid* or alginate* or hydrogel* or foam or bead or film*1 or tulle or gauze or non-adherent or non adherent or
silver or honey or matrix).tw. (340728)
10 or/1-9 (349782)
11 exp Foot Ulcer/ (6231)
12 exp Diabetic Foot/ (5195)
13 (diabet* adj3 ulcer*).tw. (2360)
14 (diabet* adj3 (foot or feet)).tw. (4521)
15 (diabet* adj3 wound*).tw. (1194)
16 (diabet* adj3 amputat*).tw. (599)
17 or/11-16 (8927)
18 10 and 17 (657)
19 exp *Comparative Effectiveness Research/ (557)
20 exp “Outcome Assessment (Health Care)”/mt, sn [Methods, Statistics & Numerical Data] (8453)
21 exp Randomized Controlled Trials as Topic/ (83097)
22 exp Meta-Analysis as Topic/ (12359)
23 exp *Treatment Outcome/ (4605)
24 (mixed treatment comparison* or indirect treatment comparison* or indirect comparison*).tw. (628)
25 (network meta-analysis or multiple treatments meta-analysis or evidence synthesis).tw. (1002)
26 or/19-25 (105754)
27 18 and 26 (557)
63Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
JoDumville: conceived, designed and co-ordinated the review, extracted and analysed data, undertook quality assessment and completed
the first draft of the review and all revisions, responded to peer referee feedback and approved the final version prior to submission.
Gill Norman: designed the review, analysed and interpreted data, checked quality assessment, and completed the first draft of the review
and approved the final version prior to submission.
Susan O’Meara: conceived and designed the review, checked data extraction and analysed the data, and completed the first draft of the
review and approved the final version prior to submission.
Sally Bell-Syer: conceived and designed the review, interpreted the data, and completed the first draft of the review and approved the
final version prior to submission.
LihuaWu : Designed the review, extracted data, undertook quality assessment, and completed the first draft of the review and approved
the final version prior to submission.
Contributions of editorial base
Nicky Cullum: edited the protocol; advised on methodology, interpretation and protocol content and approved the final review for
publication.
Joan Webster: approved the final protocol prior to submission.
Ruth Foxlee: designed the search strategy and edited the search methods section.
Gill Rizzello: administered the editorial process for the review stage.
D E C L A R A T I O N S O F I N T E R E S T
Jo Dumville: none to declare.
Gill Norman: none to declare.
Susan O’Meara: none to declare.
Sally Bell-Syer: none to declare.
Lihua Wu: none to declare.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Health Sciences, University of York, UK.
• School of Nursing, Midwifery and Social Work, University of Manchester, UK.
64Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• This project was supported by the National Institute for Health Research via Cochrane Infrastructure funding to Cochrane
Wounds, UK.
65Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
